Prisma Health Labs Reference Ranges

Inactive

PROCEDURE:

REFERENCE:

ROCHE REFERENCE:

Collaboration powered by Smartsheet | Report Abuse

Associated Policy:

Revised: 3/12/2024

Laboratory General Policy

RESPONSIBLE POSITIONS:

1. Laboratory Workforce

2. Prisma Health Providers

CLINICAL LABORATORIES:

Prisma Health Baptist Columbia Hospital Laboratory
Taylor at Marion Street
Columbia, SC 29220

Prisma Health Baptist Parkridge Hospital Laboratory
400 Palmetto Health Parkway
Columbia, SC 29212

Prisma Health Richland Hospital Central Laboratory
14 Richland Medical Park Drive
Columbia, SC 29203

Prisma Health Richland Hospital Rapid Laboratory
5 Richland Medical Park Drive
Columbia, SC 29203

Prisma Health Tuomey Hospital Laboratory
129 North Washington Street
Sumter, SC 29150

Prisma Health Baptist Easley Hospital Laboratory
200 Fleetwood Drive
Easley, SC 29640

Prisma Health Greenville Memorial Hospital Laboratory
701 Grove Road
Greenville, SC 29605

Prisma Health Greer Memorial Hospital Laboratory
830 S Buncombe Road
Greer, SC 29650

Prisma Health Hillcrest Hospital Laboratory
729 SE Main Street
Simpsonville, SC 29681

Prisma Health Laurens County Hospital Laboratory
22725 US-76
Clinton, SC 29325

Prisma Health North Greenville Hospital Laboratory
807 N Main Street
Travelers Rest, SC 29690

Prisma Health Oconee Memorial Hospital Laboratory
298 Memorial Drive
Seneca, SC 29672

Prisma Health Patewood Hospital Laboratory
175 Patewood Drive
Greenville, SC 29615

CANCER INSTITUTE LABORATORIES:

Prisma Health Cancer Institute – Eastside
65 International Dr.
Greenville, SC 29615

Prisma Health Cancer Institute – Faris Road
900 W Faris Rd
Greenville, SC 29605

Prisma Health Cancer Institute – Greer
340 Medical Pkwy
Greer, SC 29650

Prisma Health Cancer Institute – Grove Commons
3 Butternut Dr Suite B
Greenville, SC 29605

Prisma Health Cancer Institute – Laurens
22725 Hwy 76 E, 3rd Floor
Clinton, SC 29325

Prisma Health Cancer Institute – Seneca
131 Lila Doyle Dr
Seneca, SC 29672

Prisma Health Cancer Institute – Spartanburg
2400 Boiling Springs Rd
Spartanburg, SC 29316

PROCEDURE:

REFERENCE:

Acetaminophen

10 - 30 ug/mL

Adenovirus Rapid

Not Detected

Albumin

SERUM:
0 - < 1 Year 2.8 - 4.7 g/dL
1 - 60 Years 3.5 - 5.0 g/dL
> 60 Years 3.4 - 4.8 g/dL

BODY FLUID:
The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis).

Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </=1.2 g/dL is predictive of an exudate.

SERUM:
0 - 3 Days: 2.8 - 4.4 g/dL
4 Days - 13 Years: 3.8 - 5.4 g/dL
14 - 18 Years: 3.2 - 4.5 g/dL
>/= 19 Years: 3.5 - 5.2 g/dL

BODY FLUID:
The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis).

Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </= 1.2 g/dL is predictive of an exudate.

Alcohol, plasma (Medical Only)

< 10 mg/dL

< 11 mg/dL

Alkaline Phosphatase

Female:
0 - 14 Days 90 - 273 IU/L
15 Days - 11 Months 134 - 518 IU/L
1 - 9 Years 156 - 369 IU/L
10 - 12 Years 141 - 460 IU/L
13 - 14 Years 62 - 280 IU/L
15 - 16 Years 54 -128 IU/L
17 - 19 Years 48 - 95 IU/L
>/= 20 Years 40 - 150 IU/L

Male:
0 - 14 Days 90 - 273 IU/L
15 Days - 11 Months 134 - 518 IU/L
1 - 9 Years 156 - 369 IU/L
10 - 12 Years 141 - 460 IU/L
13 - 14 Years 127 - 517 IU/L
15 - 16 Years 89 - 365 IU/L
17 - 19 Years 59 - 164 IU/L
>/= 20 Years 40 - 150 IU/L

Female:
0 - 14 Days: 83 - 248 IU/L
15 Days - 11 Months: 122 - 469 IU/L
1 - 9 Years: 142 - 335 IU/L
10 - 12 Years: 129 - 417 IU/L
13 - 14 Years: 57 - 254 IU/L
15 - 16 Years: 50 - 117 IU/L
17 - 18 Years: 45 - 87 IU/L
>/= 19 Years: 35 - 104 IU/L
Male:
0 - 14 Days: 83 - 248 IU/L
15 Days - 11 Months: 122 - 469 IU/L
1 - 9 Years: 142 - 335 IU/L
10 - 12 Years: 129 - 417 IU/L
13 - 14 Years: 116 - 468 IU/L
15 - 16 Years: 82 - 331 IU/L
17 - 18 Years: 55 - 149 IU/L
>/= 19 Years 40 - 129 IU/L

Alkaline Phosphatase, Fractionated

If total Alkaline Phosphatase is elevated and labile fraction exceeds 70%- consistent with bone origin.

06/20/22

Allergens IgE - Except Peanut Components

< 0.35 kU/L

Interpretive Data:
Less than 0.10 kU/L - Normal: No significant level detected
0.10 - 0.34 kU/L - For Specialists use only: Clinical relevance undetermined
0.35 - 0.70 kU/L - Low: Indicative of ongoing sensitization
0.71 - 3.50 kU/L - Moderate: Indicative of stronger ongoing sensitization
3.51 - 17.50 kU/L - High: Indicative of high level sensitization
17.51 kU/L or Greater - Very High: Indicative of very high level sensitization

06/20/22

Allergens IgE - Peanut Components

< 0.10 kU/L

Interpretive Data:
Any detectable level (>/= 0.1 kU/L) of Specific IgE for Peanut Components may be significant.
Ara h 1, 2, 3, and 6 are the peanut proteins most linked to systemic allergic reactions, including anaphylaxis. If any one of these four components is positive, the patient has a high risk of systemic allergic reaction when exposed to peanuts, regardless of the whole peanut allergen result.
Reactivity to Ara h 9 and non-reactivity to Ara h 1,2,3 and 6 indicates a variable risk of systemic allergic reaction including anaphylaxis.
Reactivity to Ara h 8 and Profilin and non-reactivity to Ara h 1,2,3 and 6 indicates a lower risk of a systemic allergic reaction. Reactivity to CCD and non-reactive to Ara h 1,2,3 and 6 indicates lowest risk of a systemic allergic reaction.

07/07/22

Alpha 1 Antitrypsin

90 - 200 mg/dL

07/07/22

Alpha Fetoprotein Tumor Marker

< 8.79 ng/mL

ALT (SGPT)

Female:
0 - 11 Months 5 - 33 IU/L
1 - 12 Years 9 - 25 IU/L
13 - 19 Years 8 - 22 IU/L
>/= 20 Years < 55 IU/L

Male:
0 - 11 Months 5 - 33 IU/L
1 - 12 Years 9 - 25 IU/L
13 - 19 Years 9 - 24 IU/L
>/= 20 Years < 55IU/L

Female:
0 - 11 Months: </=25 IU/L
1 - 12 Years: </=19 IU/L
13 - 19 Years: </=17 IU/L
>/= 20 Years: 10 - 35 IU/L
Male:
0 - 11 Months: </=25 IU/L
1 - 12 Years: </=19 IU/L
13 - 19 Years: </=18 IU/L
>/= 20 Years: 10 - 50 IU/L

Amikacin

TROUGH:
0 - 2 Months < 5.1 ug/mL
>/= 3 Months 4.0 - 8.0 ug/mL

PEAK:
25.0 - 35.0 ug/mL

RANDOM:
8.0 - 25.0 ug/mL

Ammonia, Plasma

18 - 72 umol/L

Female:
11 - 51 umol/L

Male:
16 - 60 umol/L

Amnisure

Negative

Amylase

SERUM:
0 - 27 Days 5 - 65 IU/L
28 Days - 70 Years 25 - 125 IU/L
>/= 71 Years 20 - 160 IU/L

BODY FLUID:
Interpretive Data:
Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury.
Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture.

SERUM:
0 - 14 Days: 3 - 11 IU/L
15 - 84 Days: </=26 IU/L
85 Days - 11 Months: 3 - 58 IU/L
1 - 18 Years: 29 - 118 IU/L
>/=19 years: 28 - 100 IU/L

BODY FLUID:
Interpretive Data:
Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury.
Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture.

Anion Gap

6 - 16 mmol/L

07/07/22

Anti-Streptolysin O (ASO)

0 - 3 Years: < 100 U/mL
4 - 17 Years: < 251 U/mL
>/= 18 Years: < 200 U/mL

07/07/22

Anti-Thrombin III Assay (ATIII)

80 - 120 %

APT Fetal Hemoglobin

No fetal hemoglobin

AST (SGOT)

0 - 14 Days: 23-186 IU/L
15 Days - 11 Months: 23-83 IU/L
>/=1 Year: 5-34 IU/L

Female:
0 - 14 Days: </= 155 IU/L
15 Days - 11 Months: </= 63 IU/L
1 - 6 Years: </= 41 IU/L
7 - 11 Years: </= 33 IU/L
12 - 18 Years: </= 23 IU/L
>/= 19 Years: 10 - 35 IU/L

Male:
0 - 14 Days: </=155 IU/L
15 Days - 11 Months: </= 63 IU/L
1 - 6 Years: </= 41 IU/L
7 - 11 Years: </= 33 IU/L
12 - 18 Years: </=32 IU/L
>/= 19 Years: 10 - 50 IU/L

06/20/22

Beta-2 Glycoprotein Antibodies IgG

< 7.0 U/mL

Interpretive Data:
< 7.0 Normal
7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks.
> 10.0 Positive

The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
Expected values may vary on the population tested.

06/20/22

Beta-2 Glycoprotein Antibodies IgM

Beta HCG, Quantitative

Pregnancy:
Negative: </= 5 mIU/mL
Inconclusive: > 5 - < 25 mIU/mL
Positive: >/= 25 mIU/mL
Rare false positives have been reported. Positive results should be confirmed with a urine specimen prior to aggressive therapy.

Weeks Post Last Menstrual Period: Approx Total B-hCG Range (mIU/mL)
1-10 Weeks: <1.20 - 231,000
11-15 Weeks: 16,996 - 234,990
16-22 Weeks: 6,860 - 50,064
23-40 Weeks: 1,583 - 49,413

The ARCHITECT Total B-hCG assay is cleared for use in the early detection of pregnancy only. It is not approved for any other uses such as tumor marker screening, tumor marker monitoring, etc. and it should not be performed for any other uses.

Pregnancy:
Negative: </= 5 mIU/mL
Inconclusive: > 5 - < 25 mIU/mL
Positive: >/= 25 mIU/mL
Rare false positives have been reported. Positive results should be confirmed with a urine specimen prior to aggressive therapy.

Weeks Post Last Menstrual Period: Approx Total B-hCG Range (mIU/mL)
1 - 10 Weeks: <1.20 - 231,000
11 - 15 Weeks: 16,996 - 234,990
16 - 22 Weeks: 6,860 - 50,064
23 - 40 Weeks: 1,583 - 49,413

The ARCHITECT Total B-hCG assay is cleared for use in the early detection of pregnancy only. It is not approved for any other uses such as tumor marker screening, tumor marker monitoring, etc. and it should not be performed for any other uses.

Beta-Hydroxybutyric Acid

0.0 - 0.5 mmol/L

0.6-1.5 mmol/L w/Glucose >/=300 mg/dL
Potential for development of problem requiring medical intervention
>1.5 mmol/L w/Glucose >/=300 mg/dL
May indicate the risk of developing diabetic ketoacidosis (DKA)

0.0 - 0.5 mmol/L

0.6 - 1.5 mmol/L w/Glucose >/=300 mg/dL
Potential for development of problem requiring medical intervention
> 1.5 mmol/L w/Glucose >/=300 mg/dL
May indicate the risk of developing diabetic ketoacidosis (DKA)

Bile Acids

0.0 - 12.0 umol/L

Bilirubin, Direct

0 - 14 Days 0.3 - 0.7 mg/dL
>/= 15 Days 0.0 - 0.5 mg/dL

0 - 14 Days: 0.3 - 0.5 mg/dL
15 Days - 11 Months: </= 0.2 mg/dL
1 - 8 Years: </= 0.1 mg/dL
9 - 12 Years: </=0.2 mg/dL
13 - 18 Years:
Male: 0.1 - 0.3 mg/dL
Female: </= 0.3 mg/dL
>/= 19 Years: </= 0.3 mg/dL

Bilirubin, Indirect

0 - 14 Days 0.1 - 9.9 mg/dL
>/= 15 Days 0.0 - 1.2 mg/dL

0 - 14 Days: 0.1 - 9.9 mg/dL
>/= 15 Days: 0.0 - 1.2 mg/dL

Bilirubin, Total

0 - 23 Hours < 6.0 mg/dL
1 - 14 Days 0.1 - 10.3 mg/dL
>/= 15 Days 0.1 - 1.2 mg/dL

0 - 23 Hours: < 6.0 mg/dL
1 - 14 Days: 0.1 - 10.3 mg/dL
>/= 15 Days: 0.1 - 1.2 mg/dL

Blood Culture ID by PCR

Not Detected

Bordetella pertussis DNA

Negative

Borrelia burgdorferi Ab Total (Lyme)

Negative

Brain-Type Natriuretic Peptide (BNP)

0 Days - 11 Months < 24 pg/mL
1 Year - 5 Years < 30 pg/mL
6 Years - 10 Years < 15 pg/mL
11 Years - 14 Years < 21 pg/mL
15 Years - 20 Years < 20 pg/mL
>/=21 Years < 100 pg/mL

This assay is not performed on Roche analyzers.

NT-proBNP

0 - 74 Years </= 125 pg/mL
>/= 75 Years </= 450 pg/mL

0 - 74 Years: </= 125 pg/mL
>/= 75 Years: </= 450 pg/mL

Calcium

SERUM:
0 - 11 Months 8.5 - 11.0 mg/dL
1 - 17 Years 9.0 - 10.5 mg/dL
>/= 18 Years 8.5 - 10.4 mg/dL

URINE:
Random:
Male: 0.9 - 37.9 mg/dL
Female: 0.5 - 35.7 mg/dL

Timed:
CA Free Diet 5 - 40 mg/24hr
Low to Average Intake 50 - 150 mg/24hr
Average Intake 100 - 300 mg/24hr

0 - 11 Years: 2.0 - 4.0 mg/kg/24hr
> 12 Years: 1.4 - 4.3 mg/kg/24hr

SERUM:
0 - 11 Months: 8.6 - 11.0 mg/dL
1 - 17 Years: 9.3 - 10.6 mg/dL
18 - 60 Years: 8.6 - 10.0 mg/dL
60 - 90 Years: 8.8 - 10.2 mg/dL
>/= 91 Years: 8.2 - 9.6 mg/dL

URINE:
Random:
Male: 0.9 - 37.9 mg/dL
Female: 0.5 - 35.7 mg/dL

Timed:
CA Free Diet 5 - 40 mg/24hr
Low to Average Intake 50 - 150 mg/24hr
Average Intake 100 - 300 mg/24hr

0 - 11 Years: 2.0 - 4.0 mg/kg/24hr
>/= 12 Years: 1.4 - 4.3 mg/kg/24hr

Calcium/Creatinine Ratio, Urine

Male: < 0.25 mgca/mgcr
Female: < 0.33 mgca/mgcr

Male: < 0.24 mgca/mgcr
Female: < 0.33 mgca/mgcr

Calcium, Ionized

WHOLE BLOOD: (Upstate)
0 - 29 Days: 1.00 - 1.50 mmol/L
1 - 6 Months: 0.95 - 1.50 mmol/L
>/= 7 Months: 1.16 - 1.32 mmol/L

PLASMA: (Midlands)
All Ages: 1.09 - 1.30 mmol/L

Calcium, Ionized Pre-Filter and Post Filter

WHOLE BLOOD: (Upstate)
1.16 - 1.32 mmol/L

PLASMA: (Midlands)
1.09 - 1.30 mmol/L

Cancer Antigen 125 (CA 125)

< 35.1 U/mL

100

Cancer Antigen 15-3 (CA 15-3)

< 23.6 U/mL

101

102

Cancer Antigen 19-9 (CA 19-9)

< 35.1 U/mL

103

104

Carbamazepine (Tegretol)

4.0 - 12.0 ug/mL

105

106

Carbapenemase by PCR Screen/Isolate

Not Detected

107

108

Carcinoembryonic Antigen (CEA)

< 3.1 ng/mL

109

110

06/20/22

Cardiolipin Antibody IgA

< 14.0 APL U/mL

Interpretive Data:
< 14.0 Negative
14.0-20.0 Equivocal - Recommend to retest the patient after 4-6 weeks.
> 20.0 Positive

Antibody prevalence in autoimmune patients varies widely depending on disease area. The proportion of sera from a normal population found positive for the Cardiolipin IgA covered by the EliA Cardiolipin IgA test is below 5%, increasing with age, and men tend to show higher values. Expected values may vary depending on the population tested.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

111

112

06/20/22

Cardiolipin Antibody IgG

< 10.0 GPL U/mL

Interpretive Data:
< 10.0 Negative
10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks.
> 40.0 Positive

The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS:
Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24%
Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

113

114

06/20/22

Cardiolipin Antibody IgM

< 10.0 MPL U/mL

Interpretive Data:
< 10.0 Negative
10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks.
> 40.0 Positive

The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS:
Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24%
Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

115

116

CD4 Level/ T&B Cell Enumeration Panel (CD3, CD4, CD8, CD19, CD16/56) / T Helper/Suppressor, Whole Blood(CD3, CD4, CD8)

Midlands:

117

CD3 (T Cells), Whole Blood

0 - 2 Months: 53.0 - 84.0 %
3 - 5 Months: 51.0 - 77.0 %
6 - 11 Months: 49.0 - 76.0 %
12 - 23 Months: 53.0 - 75.0 %
2 - 5 Years: 56.0 - 75.0 %
6 - 11 Years: 60.0 - 76.0 %
12 - 17 Years: 56.0 - 84.0 %
>/= 18 Years: 58.0 - 84.0 %

118

CD3 Absolute Count, Whole Blood

0 - 2 Months 2500 - 5500 Cells/uL
3 - 5 Months 2500 - 5600 Cells/uL
6 - 11 Months 1900 - 5900 Cells/uL
12 - 23 Months 2100 - 6200 Cells/uL
2 - 5 Years 1400 - 3700 Cells/uL
6 - 11 Years 1200 - 2600 Cells/uL
12 - 17 Years 1000 - 2200 Cells/uL
>/= 18 Years 856 - 2237 Cells/uL

119

CD4 (Helper T Cells), Whole Blood

0 - 2 Months 35.0 - 64.0 %
3 - 5 Months 35.0 - 56.0 %
6 - 11 Months 31.0 - 56.0 %
12 - 23 Months 32.0 - 51.0 %
2 - 5 Years 28.0 - 47.0 %
6 - 11 Years 31.0 - 47.0 %
12 - 17 Years 31.0 - 52.0 %
>/= 18 Years 33.6 - 64.8 %

120

CD4 Absolute Count, Whole Blood

0 - 2 Months 1600 - 4000 Cells/uL
3 - 5 Months 1800 - 4000 Cells/uL
6 - 11 Months 1400 - 4300 Cells/uL
12 - 23 Months 1300 - 3400 Cells/uL
2 - 5 Years 700 - 2200 Cells/uL
6 - 11 Years 650 - 1500 Cells/uL
12 - 17 Years 530 - 1300 Cells/uL
>/= 18 Years 518 - 1472 Cells/uL

121

CD8 (Suppressor T Cells), Whole Blood

0 - 2 Months 12.0 - 28.0 %
3 - 5 Months 12.0 - 23.0 %
6 - 11 Months 12.0 - 24.0 %
12 - 23 Months 14.0 - 30.0 %
2 - 5 Years 16.0 - 30.0 %
6 - 17 Years 18.0 - 35.0 %
>/= 18 Years 13.0 - 37.6 %

122

CD8 Absolute Count, Whole Blood

0 - 2 Months 560 - 1700 Cells/uL
3 - 5 Months 590 - 1600 Cells/uL
6 - 11 Months 500 - 1700 Cells/uL
12 - 23 Months 620 - 2000 Cells/uL
2 - 5 Years 490 - 1300 Cells/uL
6 - 11 Years 370 - 1100 Cells/uL
12 - 17 Years 330 - 920 Cells/uL
>/= 18 Years 205 - 924 Cells/uL

123

CD16/56 NK Cells, Whole Blood

0 - 2 Months 4.0 - 18.0 %
3 - 5 Months 3.0 - 14.0 %
6 - 11 Months 3.0 - 15.0 %
2 - 11 Years 4.0 - 17.0 %
12 - 17 Years 3.0 - 22.0 %
>/= 18 Years 4.3 - 26.6 %

124

CD16/56 Absolute Count, Whole Blood

0 - 2 Months 170 - 1100 Cells/uL
3 - 5 Months 170 - 830 Cells/uL
6 - 11 Months 160 - 950 Cells/uL
12 - 23 Months 180 - 920 Cells/uL
2 - 5 Years 130 - 720 Cells/uL
6 - 11 Years 100 - 480 Cells/uL
12 - 17 Years 70 - 480 Cells/uL
>/= 18 Years 74 - 562 Cells/uL

125

CD19 % (B cells), Whole Blood

0 - 2 Months 6.0 - 32.0 %
3 - 5 Months 11.0 - 41.0 %
6 - 11 Months 14.0 - 37.0 %
12 - 23 Months 16.0 - 35.0 %
2 - 5 Years 14.0 - 33.0 %
6 - 11 Years 13.0 - 27.0 %
12 - 17 Years 6.0 - 23.0 %
>/= 18 Years 5.7 - 24.9 %

126

CD19 Absolute Count, Whole Blood

0 - 2 Months 300 - 2000 Cells/uL
3 - 5 Months 430 - 3000 Cells/uL
6 - 11 Months 610 - 2600 Cells/uL
12 - 23 Months 720 - 2600 Cells/uL
2 - 5 Years 390 - 1400 Cells/uL
6 - 11 Years 270 - 860 Cells/uL
12 - 17 Years 110 - 570 Cells/uL
>/= 18 Years 87 - 507 Cells/uL

127

128

Cell Count, Fluid

CSF:
Nucleated Cells:
0 - 1 Year: 0-22 Cells/uL
1 - 12 Years: 0 - 7 Cells/uL
> 12 Years: 0 - 5 Cells/uL

RBCs: 0 - 2 Cells/uL

BODY FLUID:
Nucleated Cells:
Synovial Fluids: 0-150 mm3
All Other Fluids: 0-500 mm3

129

130

Chlamydia trachomatis, NAAT

Negative

131

132

Chloride

SERUM:
0 - 29 Days: 98 - 113 mmol/L
>/= 30 Days: 98 - 107 mmol/L

URINE:
Random: No Reference Ranges Established

Timed: Varies significantly with hydration and chloride intake.
0 - 27 Days: No Reference Ranges Established
28 Days - 23 Months: 2 - 10 mmol/24 hrs
2 - 17 Years: 15 - 40 mmol/24 hrs
>/= 18 Years: 110 - 250 mmol/24 hrs

133

134

Chloride, Sweat

0 - 29 mmol/L

Interpretive Data:
</= 29 mmol/L - CF unlikely
30-59 mmol/L - Intermediate range, needs further study to establish or rule out a CF diagnosis.
>/= 60 mmol/L - Indicative of CF for individuals presenting with a positive screen, clinical features consistent with CF, or a positive family history.

135

136

CKMB

Male: < 7.3 ng/mL
Female: < 3.5 ng/mL

Male: < 7.7 ng/mL
Female: < 4.3 ng/mL

137

138

Clostridium Difficile Toxin B gene by PCR

Negative

139

140

CO2

0 - 27 Days: 15 - 22 mmol/L
28 Days - 11 Months: 20 - 28 mmol/L
>/= 1 Year: 20 - 30 mmol/L

0 - 27 Days: 14 - 27 mmol/L
28 Days - 11 Months: 20 - 28 mmol/L
>/= 1 Year: 22 - 29 mmol/L

141

142

Complement, C-3

0 - 11 Months: 50 - 160 mg/dL
1 - 13 Years: 80 - 173 mg/dL
>/= 14 Years: 82 - 193 mg/dL

143

144

Complement, C-4

0 - 11 Months: 7 - 30 mg/dL
1 - 13 Years: 13 - 46 mg/dL
>/= 14 Years: 15 - 57 mg/dL

145

146

Complete Blood Count (CBC):

147

WBC

Male:
0 - 14 Days 8.0 - 15.4 K/uL
15 - 30 Days 7.8 - 15.9 K/uL
31 - 60 Days 8.1 - 15.0 K/uL
2 - 5 Months 6.5 - 13.3 K/uL
6 - 23 Months 6.0 - 13.4 K/uL
2 - 5 Years 5.1 - 13.4 K/uL
6 - 11 Years 4.3 - 11.0 K/uL
12 - 17 Years 3.8 - 9.8 K/uL
>/= 18 Years 3.5 - 10.8 K/uL

Female:
0 - 14 Days 8.2 - 14.6 K/uL
15 - 30 Days 8.4 - 14.4 K/uL
31 - 60 Days 7.1 - 14.7 K/uL
2 - 5 Months 6.0 - 13.3 K/uL
6 - 23 Months 6.5 - 13.0 K/uL
2 - 5 Years 4.9 - 13.2 K/uL
6 - 11 Years 4.3 - 11.4 K/uL
12 - 17 Years 4.2 - 9.4 K/uL
>/=18 Years 3.5 - 10.8 K/uL

148

RBC

Male:
0 - 14 Days: 4.10 - 5.55 M/uL
15 - 30 Days: 3.16 - 4.63 M/uL
31 - 60 Days: 3.02 - 4.22 M/uL
2 - 5 Months: 3.43 - 4.80 M/uL
6 - 23 Months: 4.03 - 5.07 M/uL
2 - 5 Years: 3.89 - 4.97 M/uL
6 - 11 Years: 3.96 - 5.03 M/uL
12 - 17 Years: 4.03 - 5.29 M/uL
>/= 18 Years: 4.17 - 5.89 M/uL

Female:
0 - 14 Days: 4.12 - 5.74 M/uL
15 - 30 Days: 3.32 - 4.80 M/uL
31 - 60 Days: 2.93 - 3.87 M/uL
2 - 5 Months: 3.45 - 4.75 M/uL
6 - 23 Months: 3.97 - 5.01 M/uL
2 - 5 Years: 3.84 - 4.92 M/uL
6 - 11 Years: 3.90 - 4.96 M/uL
12 - 17 Years: 3.93 - 4.90 M/uL
>/= 18 Years: 3.86 - 5.35 M/uL

149

HGB

Male:
0 - 14 Days: 13.9 - 19.1 g/dL
15 - 30 Days: 10.0 - 15.3 g/dL
31 - 60 Days: 8.9 - 12.7 g/dL
2 - 5 Months: 9.6 - 12.4 g/dL
6 - 23 Months: 10.1 - 12.5 g/dL
2 - 5 Years: 10.2 - 12.7 g/dL
6 - 11 Years: 10.7 - 13.4 g/dL
12 - 17 Years: 11.0 - 14.5 g/dL
>/= 18 Years: 12.7 - 17.2 g/dL

Female:
0 - 14 Days: 13.4 - 20.0 g/dL
15 - 30 Days: 10.8 - 14.6 g/dL
31 - 60 Days: 9.2 - 11.4 g/dL
2 - 5 Months: 9.9 - 12.4 g/dL
6 Months - 5 Years: 10.2 - 12.7 g/dL
6 - 11 Years: 10.6 - 13.2 g/dL
12 - 17 Years: 10.8 - 13.3 g/dL
>/= 18 Years: 11.0 - 15.4 g/dL

150

HCT

Male:
0 - 14 Days: 39.8 - 53.6 %
15 - 30 Days: 30.5 - 45.0 %
31 - 60 Days: 26.8 - 37.5 %
2 - 5 Months: 28.6 - 37.2 %
6 - 23 Months:30.8 - 37.8 %
2 - 5 Years: 31.0 - 37.7 %
6 - 11 Years: 32.2 - 39.8 %
12 - 17 Years: 33.9 - 43.5 %
>/= 18 Years: 39.4 - 51.6 %

Female:
0 - 14 Days: 39.6 - 57.2 %
15 - 30 Days: 32.0 - 44.5 %
31 - 60 Days: 27.7 - 35.1 %
2 - 5 Months: 29.5 - 37.1 %
6 - 23 Months:30.9 - 37.9 %
2 - 5 Years: 31.2 - 37.8 %
6 - 11 Years: 32.4 - 39.5 %
12 - 17 Years: 33.4 - 40.4 %
>/= 18 Years: 35.6 - 47.3 %

151

MCV

Male:
0 - 14 Days: 91.3 - 103.1 fL
15 - 30 Days: 89.4 - 99.7 fL
31 - 60 Days: 84.3 - 94.2 fL
2 - 5 Months: 74.1 - 87.5 fL
6 - 23 Months:69.5 - 81.7 fL
2 - 5 Years: 71.3 - 84.0 fL
6 - 11 Years: 74.4 - 86.1 fL
12 - 17 Years: 76.7 - 89.2 fL
>/= 18 Years: 79.0 - 100.0 fL

Female:
0 - 14 Days: 92.7 - 106.4 fL
15 - 30 Days: 90.1 - 103.0 fL
31 - 60 Days: 83.4 - 96.4 fL
2 - 5 Months: 74.8 - 88.3 fL
6 - 23 Months:71.3 - 82.6 fL
2 - 5 Years: 72.3 - 85.0 fL
6 - 11 Years: 75.9 - 87.6 fL
12 - 17 Years: 76.9 - 90.6 fL
>/= 18 Years: 79.0 - 100.0 fL

152

MCH

Male:
0 - 14 Days: 31.3 - 35.6 pg
15 - 30 Days: 29.9 - 34.1 pg
31 - 60 Days: 27.8 - 32.0 pg
2 - 5 Months: 24.4 - 28.9 pg
6 - 23 Months:22.7 - 27.2 pg
2 - 5 Years: 23.7 - 28.3 pg
6 - 11 Years: 24.9 - 29.2 pg
12 - 17 Years: 25.2 - 30.2 pg
>/= 18 Years: 25.7 - 33.2 pg

Female:
0 - 14 Days: 31.1 - 35.9 pg
15 - 30 Days: 30.4 - 35.3 pg
31 - 60 Days: 28.0 - 32.5 pg
2 - 5 Months: 24.4 - 29.5 pg
6 - 23 Months:23.2 - 27.5 pg
2 - 5 Years: 23.7 - 28.6 pg
6 - 11 Years: 24.8 - 29.5 pg
12 - 17 Years: 24.8 - 30.2 pg
>/= 18 Years: 23.7 - 32.9 pg

153

MCHC

Male:
0 - 14 Days: 33.0 - 35.7 g/dL
15 - 30 Days: 32.7 - 35.1 g/dL
31 - 60 Days: 32.3 - 34.8 g/dL
2 - 5 Months: 31.9 - 34.4 g/dL
6 - 23 Months:31.6 - 34.4 g/dL
2 - 5 Years: 32.0 - 34.7 g/dL
6 - 11 Years: 32.2 - 34.9 g/dL
12 - 17 Years: 31.8 - 34.8 g/dL
>/= 18 Years: 30.0 - 36.5 g/dL

Female:
0 - 14 Days: 33.4 - 35.4 g/dL
15 - 30 Days: 33.2 - 35.0 g/dL
31 -60 Days: 32.5 - 34.9 g/dL
2 - 5 Months: 32.1 - 34.4 g/dL
6 - 23 Months:31.9 - 34.2 g/dL
2 - 11 Years: 31.8 - 34.6 g/dL
12 - 17 Years: 31.5 - 34.2 g/dL
>/= 18 Years: 30.0 - 36.5 g/dL

154

RDW-CV

Male:
0 - 14 Days: 14.8 - 17.0 %
15 - 30 Days: 14.3 - 16.8 %
31 - 60 Days: 13.8 - 16.1 %
2 - 5 Months: 12.4 - 15.3 %
6 - 23 Months:12.9 - 15.6 %
2 - 5 Years: 12.5 - 14.9 %
6 - 11 Years: 12.3 - 14.1 %
12 - 17 Years: 12.4 - 14.5 %
>/= 18 Years: 11.6 - 16.0 %

Female:
0 - 14 Days: 14.6 - 17.3 %
15 - 30 Days: 14.4 - 16.2 %
31 - 60 Days: 13.6 - 15.8 %
2 - 5 Months: 12.2 - 14.3 %
6 - 23 Months:12.7 - 15.1 %
2 - 5 Years: 12.4 - 14.9 %
6 - 11 Years: 12.2 - 14.4 %
12 - 17 Years: 12.3 - 14.6 %
>/= 18 Years: 11.6 - 16.0 %

155

RDW-SD

Male:
0 - 14 Days: 51.0 - 61.7 fL
15 - 30 Days: 46.3 - 57.3 fL
31 - 60 Days: 43.9 - 52.8 fL
2 - 5 Months: 35.3 - 45.7 fL
6 - 23 Months:35.3 - 45.7 fL
2 - 5 Years: 35.3 - 42.8 fL
6 - 11 Years: 35.1 - 41.7 fL
12 - 17 Years: 36.7 - 43.8 fL
>/= 18 Years: 35.1 - 43.9 fL

Female:
0 - 14 Days: 51.4 - 65.7 fL
15 - 30 Days: 47.2 - 59.8 fL
31 - 60 Days: 43.0 - 55.0 fL
2 - 5 Months: 35.2 - 45.1 fL
6 - 23 Months:34.9 - 42.4 fL
2 - 5 Years: 34.9 - 42.0 fL
6 - 11 Years: 35.5 - 41.8 fL
12 - 17 Years: 37.1 - 44.2 fL
>/= 18 Years: 36.4 - 46.3 fL

156

MPV

Male:
0 - 14 Days: 10.2 - 11.9 fL
15 - 30 Days: 10.1 - 12.1 fL
31 - 60 Days: 9.2 - 10.8 fL
2 - 5 Months: 8.9 - 10.6 fL
6 - 23 Months:8.7 - 10.5 fL
2 - 5 Years: 9.0 - 10.9 fL
6 - 11 Years: 9.2 - 11.4 fL
12 - 17 Years: 9.6 - 11.8 fL
>/= 18 Years:
Sysmex: 9.2 - 12.8 fL
Beckman: 6.9 - 10.6 fL

Female:
0 - 14 Days: 10.4 - 12.0 fL
15 - 30 Days: 10.0 - 12.2 fL
31 - 60 Days: 9.4 - 11.1 fL
2 - 5 Months: 9.0 - 10.9 fL
6 - 23 Months: 8.8 - 10.6 fL
2 - 5 Years: 8.9 - 11.0 fL
6 - 11 Years: 9.3 - 11.3 fL
12 - 17 Years: 9.6 - 11.7 fL
>/= 18 Years:
Sysmex: 9.2 - 12.8 fL
Beckman: 6.9 - 10.6 fL

157

Platelet Count

Male:
0 - 14 Days: 218 - 419 K/uL
15 - 30 Days: 248 - 586 K/uL
31 - 60 Days: 229 - 562 K/uL
2 - 5 Months: 244 - 529 K/uL
6 - 23 Months:206 - 445 K/uL
2 - 5 Years: 202 - 403 K/uL
6 - 11 Years: 206 - 369 K/uL
12 - 17 Years: 175 - 332 K/uL
>/= 18 Years: 150 - 400 K/uL

Female:
0 - 14 Days: 144 - 449 K/uL
15 - 30 Days: 279 - 571 K/uL
31 - 60 Days: 331 - 597 K/uL
2 - 5 Months: 247 - 580 K/uL
6 - 23 Months:214 - 459 K/uL
2 - 5 Years: 189 - 394 K/uL
6 - 11 Years: 199 - 367 K/uL
12 - 17 Years: 194 - 345 K/uL
>/= 18 Years: 150 - 400 K/uL

158

Nucleated RBCs

ABSOLUTE:
0 - 3 Days: 0.1 - 8.3
>/= 4 Days: 0.0 - 0.2

PERCENT:
0 - 3 Days: 0 - 8 %
>/= 4 Days: 0 %

159

Differential White Count

160

Neutrophils, Absolute

Male:
0 - 14 Days: 1.60 - 6.06 K/uL
15 - 30 Days: 1.18 - 5.45 K/uL
31 - 60 Days: 0.83 - 4.23 K/uL
61 - 180 Days:0.97 - 5.45 K/uL
6 - 23 Months:1.19 - 7.21 K/uL
2 - 5 Years: 1.54 - 7.92 K/uL
6 - 11 Years: 1.63 - 7.55 K/uL
12 - 17 Years: 1.54 - 7.04 K/uL
>/= 18 Years: 1.78 - 5.38 K/uL

Female:
0 - 14 Days: 1.73 - 6.75 K/uL
15 - 30 Days: 1.23 - 4.80 K/uL
31 - 60 Days: 1.00 - 4.68 K/uL
61 - 180 Days:1.04 - 7.20 K/uL
6 - 23 Months:1.27 - 7.18 K/uL
2 - 5 Years: 1.60 - 8.29 K/uL
6 - 11 Years: 1.64 - 7.87 K/uL
12 - 17 Years: 1.82 - 7.47 K/uL
>/= 18 Years: 1.56 - 6.13 K/uL

161

Lymphocytes, Absolute

Male
0 - 14 Days: 2.07 - 7.53 K/uL
15 - 30 Days: 2.11 - 8.38 K/uL
31 - 60 Days: 2.47 - 7.95 K/uL
61 - 180 Days: 2.45 - 8.89 K/uL
6 - 23 Months: 1.56 - 7.83 K/uL
2 - 5 Years: 1.13 - 5.52 K/uL
6 - 11 Years: 0.97 - 3.96 K/uL
12 - 17 Years 0.97 - 3.26 K/uL
>/= 18 Years: 1.32 - 3.57 K/uL

Female
0 - 14 Days: 1.75 - 8.00 K/uL
15 - 30 Days: 2.42 - 8.20 K/uL
31 - 60 Days: 2.29 - 9.14 K/uL
61 - 180 Days: 2.14 - 8.99 K/uL
6 - 23 Months: 1.52 - 8.99 K/uL
2 - 5 Years: 1.25 - 5.77 K/uL
6 - 11 Years: 1.16 - 4.28 K/uL
12 - 17 Years: 1.16 - 3.33 K/uL
>/= 18 Years: 1.18 - 3.74 K/uL

162

Monocytes, Absolute

Male:
0 - 14 Days: 0.52 - 1.77 K/uL
15 - 30 Days: 0.28 - 1.38 K/uL
31 - 60 Days: 0.28 - 1.05 K/uL
2 - 5 Months: 0.28 - 1.07 K/uL
6 - 23 Months: 0.25 - 1.15 K/uL
24 - 35 Months: 0.19 - 0.94 K/uL
3 - 5 Years: 0.30 - 0.90 K/uL
6 - 16 Years: 0.20 - 0.80 K/uL
>/= 17 Years: 0.30 - 0.82 K/uL

Female:
0 - 14 Days: 0.57 - 1.72 K/uL
15 - 30 Days: 0.42 - 1.21 K/uL
31 - 60 Days: 0.28 - 1.21 K/uL
2 - 5 Months: 0.24 - 1.17 K/uL
6 - 23 Months: 0.26 - 1.08 K/uL
24 - 35 Months: 0.24 - 0.92 K/uL
3 - 5 Years: 0.30 - 0.90 K/uL
6 - 16 Years: 0.20 - 0.80 K/uL
>/= 17 Years: 0.24 - 0.86 K/uL

163

Eosinophils, Absolute

Male:
0 - 14 Days: 0.12 - 0.66 K/uL
15 - 30 Days: 0.08 - 0.80 K/uL
31 - 60 Days: 0.05 - 0.57 K/uL
2 - 5 Months: 0.03 - 0.61 K/uL
6 - 23 Months: 0.02 - 0.82 K/uL
24 - 35 Months: 0.03 - 0.53 K/uL
3 - 11 Years: 0.00 - 0.50 K/uL
12 - 16 Years: 0.10 - 0.20 K/uL
>/= 17 Years: 0.04 - 0.54 K/uL

Female:
0 - 14 Days: 0.09 - 0.64 K/uL
15 - 30 Days: 0.06 - 0.75 K/uL
31 - 60 Days: 0.04 - 0.63 K/uL
2 - 5 Months: 0.02 - 0.74 K/uL
6 - 23 Months: 0.02 - 0.58 K/uL
24 - 35 Months: 0.03 - 0.46 K/uL
3 - 11 Years: 0.00 - 0.50 K/uL
12- 16 Years: 0.10 - 0.20 K/uL
>/= 17 Years 0.04 - 0.36 K/uL

164

Basophils, Absolute

Male:
0 - 14 Days: 0.02 - 0.11 K/uL
15 - 30 Days: 0.01 - 0.07 K/uL
2 - 35 Months: 0.01 - 0.06 K/uL
3 - 16 Years: 0.00 - 0.10 K/uL
>/= 17 Years: 0.01 - 0.08 K/uL

Female:
0 - 14 Days 0.02 - 0.07 K/uL
15 - 30 Days: 0.01 - 0.06 K/uL
31 - 60 Days: 0.01 - 0.05 K/uL
2 - 5 Months: 0.01 - 0.07 K/uL
6 - 35 Months: 0.01 - 0.06 K/uL
3 - 16 Years: 0.00 - 0.10 K/uL
>/= 17 Years: 0.01 - 0.08 K/uL

165

Immature Granulocytes, Absolute

0.00 - 0.03 K/uL

166

Unidentified Cells, %

167

168

Cortisol

0 - 14 Days: 0.5 - 12.3 ug/dL
15 Days - 11 Months: 0.5 - 16.6 ug/dL
1 - 8 Years: 1.7 - 10.8 ug/dL
9 - 13 Years: 2.2 - 12.7 ug/dL
14 - 16 Years: 2.8 - 16.4 ug/dL
17 - 19 Years: 3.5 - 18.3 ug/dL
>/= 20 Years:
Before 10 am 3.7 - 19.4
After 10 am 2.9 - 17.3

0 - 30 Days: 0.5 - 14.0 ug/dL
1 - 11 Months: 0.7 - 20.0 ug/dL
1 - 11 Years: 2.4 - 15.0 ug/dL
12 - 18 Years: 3.6 - 17.0 ug/dL
>/= 19 Years:
Morning hours (6 - 10 am): 4.8 - 19.5 ug/dL
Afternoon hours (4 - 8 pm): 2.5 - 11.9 ug/dL

169

170

Cortisol Stimulation

> 20 ug/dL

171

172

09/06/22

Cotinine

Negative

173

09/06/22

174

COVID-19 PCR

Negative

175

176

COVID-19 IgG

Negative

177

178

07/07/22

C-peptide

0.78 - 5.19 ng/mL

179

07/07/22

180

C-Reactive Protein (CRP)

INFLAMMATION:
0 - 12 Months </=15.2
1 - 6 Years: </=25.3
6 - 11 Years: </=11.8
11 - 15 Years: </=18.1
15 - 21 Years: </=24.2
>/= 21 Years: </=5.0

INFLAMMATION:
0 - 12 Months: </= 15.2
1 - 6 Years: </= 25.3
6 - 11 Years: </= 11.8
11 - 15 Years: </= 18.1
15 - 21 Years: </= 24.2
>/= 21 Years: </= 5.0

181

182

Creatinine

SERUM:
0 - 14 Days: 0.42-1.05 mg/dL
15 Days - 11 Months:0.31-0.53 mg/dL
1 - 11 Years: 0.39-0.69 mg/dL
12 - 14 Years: 0.57-0.80 mg/dL
15 - 17 Years:
Male :0.65-1.10 mg/dL
Female: 0.59-0.88 mg/dL
>/= 18 Years:
Male: 0.72-1.25 mg/dL
Female: 0.57-1.11 mg/dL

URINE:
Random: No Established Reference Range

Timed/24 Hr:
Male: 950 - 2490 mg/24 hours
Female: 710 - 1650 mg/24 hours

Timed Concentration:
Male: 63 - 166 mg/dL
Female: 47 - 110 mg/dL

Clearance:
Male: 66 - 163 mL/min/1.73 m2
Female: 66 - 165 mL/min/1.73 m2

24 hr Excretion (Output):
0 - 23 Months: 9.0-18.0 mg/kg/24 hr
2 - 12 Years: 18.0-24.0 mg/kg/24 hr
13 - 17 Years:
Male: 27.0-30.0 mg/kg/24 hr
Female: 18.0-24.0 mg/kg/24hr
>/=18 Years:
Male:12.1 - 28.9 mg/kg/24hr
Female:10.7 - 26.0 mg/kg/24hr

BODY FLUID:
Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen.

SERUM:
0 - 3 Days: 0.30 - 1.00 mg/dL
4 Days - 11 Months: 0.20 - 0.40 mg/dL
1 - 11 Years: 0.30 - 0.70 mg/dL
12 - 14 Years: 0.50 - 1.00 mg/dL
15 - 17 Years:
Male: 0.65 - 1.10 mg/dL
Female: 0.59 - 0.88 mg/dL
>/= 18 Years:
Male: 0.67 - 1.17 mg/dL
Female: 0.51 - 0.95 mg/dL

URINE:
Random: No Established Reference Range

Timed/24 Hr:
Male: 980 - 2200 mg/24 hours
Female: 720 - 1510 mg/24 hours

Timed Concentration:
Male: 40.00 - 278.00 mg/dL
Female: 29.00 - 226.00 mg/dL

Clearance:
66 - 143 mL/min/1.73 m2

24 hr Excretion (Output):
0 - 23 Months: 9.0 - 18.0 mg/kg/24 hr
2 - 12 Years: 18.0 - 24.0 mg/kg/24 hr
13 - 17 Years:
Male: 27.0 - 30.0 mg/kg/24 hr
Female: 18.0 - 24.0 mg/kg/24hr
>/=18 Years:
Male:12.1 - 28.9 mg/kg/24hr
Female:10.7 - 26.0 mg/kg/24hr

BODY FLUID:
Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen.

183

184

Creatine Phosphokinase (CPK)

Male: 30 - 200 U/L
Female: 29 - 168 U/L

Male: 20 - 200 IU/L
Female: 20 - 180 IU/L

185

186

Cryptococcal Antigen, Blood/CSF

Negative

187

188

Cryptosporidium Antigen

Negative

189

190

Cryptosporidium Stain

Absent

191

192

Crystals, Body Fluid

No crystals identified

193

194

06/01/22

Cyclic Citrullinated Peptide (CCP) AB EliA

0.4 - 6.9 U/mL

Interpretive Data:
0.4-6.9: Negative
7.0-10.0: Equivocal
> 10.0: Positive

195

196

Cyclosporine

Upstate:
100.0 - 200.0 ng/mL

Midlands:
100 - 400 ng/mL

Interpretive Data:
Therapeutic ranges are poorly defined. They are related to clinical protocol, the organ transplanted, time following transplantation, organ function, and coadministration of other drugs. Ranges are also method and specimen dependent.

100 - 400 ng/mL

197

198

07/11/22

Cytomegalovirus (CMV) IgG

Negative

199

07/11/22

200

07/11/22

Cytomegalovirus (CMV) IgM

Negative

201

07/11/22

202

D-Dimer FEU

< 0.50 ug/mL

Interpretive Data:
For Outpatients with a value of less than 0.50 ug/ml FEU and with low to moderate clinical pretest probability, this method is FDA cleared to exclude pulmonary emoblism (PE) and as an aid in the diagnosis of deep venous thrombosis (DVT).

203

204

09/06/22

DHEA Sulfate

Male:
11 Years - 14 Years: 26.0 - 380.0 ug/dL
15 Years - 20 Years: 86.0 - 634.0 ug/dL
21 Years - 24 Years: 238.4 - 539.3 ug/dL
25 Years - 34 Years: 167.9 - 591.9 ug/dL
35 Years - 44 Years: 139.7 - 484.4 ug/dL
45 Years - 54 Years: 136.2 - 447.6 ug/dL
55 Years - 64 Years: 48.6 - 361.8 ug/dL
65 Years - 69 Years: 228.5 - 283.6 ug/dL
>/= 70 Years 34.5 - 568.9 ug/dL

Female:
11 Years - 14 Years: 26.0 - 380.0 ug/dL
15 Years - 20 Years: 50.0 - 459.0 ug/dL
21 Years - 24 Years: 134.2 - 407.4 ug/dL
25 Years - 34 Years: 95.8 - 511.7 ug/dL
35 Years - 44 Years: 74.8 - 410.2 ug/dL
45 Years - 54 Years: 56.2 - 282.9 ug/dL
55 Years - 64 Years: 29.7 - 182.2 ug/dL
65 Years - 69 Years: 33.6 - 78.9 ug/dL
>/= 70 Years 25.9 - 460.2 ug/dL

205

09/06/22

206

Digoxin

0.8 - 2.0 ng/mL

207

208

Dilantin Total (Phenytoin)

Total: 10.0 - 20.0 ug/mL

Free: 1.0 - 2.0 ug/mL

Free %: 10 - 20%

209

210

09/07/22

Dilute Russell Viper Venom (dRVVT)

No evidence of phospholipid inhibitor

211

09/07/22

212

Drug Screen, Urine

213

07/07/22

Alcohol

Negative (cutoff 40 ng/mL)

214

Amphetamines

Negative (cutoff 500 ng/mL)

215

Barbiturates

Negative (cutoff 200 ng/mL)

216

Benzodiazepines

Negative (cutoff 200 ng/mL)

217

Buprenorphine

Negative (cutoff 5 ng/mL)

218

Cannabinoids

Negative (cutoff 50 ng/mL)

219

Cocaine Metabolites

Negative (cutoff 150 ng/mL)

220

07/07/22

Codeine

Negative (cutoff 2000 ng/mL)

221

Ecstasy (MDMA)

Negative (cutoff 500 ng/mL)

222

07/07/22

Metamphetamine

Negative (cutoff 500 ng/mL)

223

Methadone

Negative (cutoff 300 ng/mL)

224

07/07/22

Morphine

Negative (cutoff 2000 ng/mL)

225

Opiates

Negative (cutoff 300 ng/mL)

226

Oxycodone

Negative (cutoff 100 ng/mL)

227

Phencyclidine

Negative (cutoff 25 ng/mL)

228

Tramadol

Negative (cutoff 200 ng/mL)

229

07/07/22

Tricyclics

Negative (cutoff 300 ng/mL)

230

Fentanyl

Negative (cutoff 1 ng/mL)

231

232

07/11/22

Epstein Barr Virus (EBV) VCA IgG

Negative

233

07/11/22

234

07/11/22

Epstein Barr Virus (EBV) VCA IgM

Negative

235

07/11/22

236

Erythrocyte Sedimentation Rate (ESR)

ESR PLUS:
Male:
0 - 49 Years: 0-15 mm/hr
50 - 84 Years: 0-20 mm/hr
>/= 85 Years: 0-30 mm/hr

Female:
0 - 49 Years: 0-20 mm/hr
50 - 84 Years: 0-30 mm/hr
>/= 85 Years: 0-42 mm/hr

ISED:
Male:
0 - 11 Months: 0 - 2 mm/hr
1 - 11 Years: 3 - 13 mm/hr
12 - 49 Years: 0 - 15 mm/hr
>/= 50 Years: 0 - 20 mm/hr

Female:
0 - 11 Months: 0 - 2 mm/hr
1 - 11 Years: 3 - 13 mm/hr
12 - 49 Years: 0 - 20 mm/hr
>/= 50 Years: 0 - 30 mm/hr

237

238

Estradiol

Male: 11 - 44 pg/mL

Female:
Pre-pubertal: < 20 pg/mL
Follicular phase: 21-251 pg/mL
Mid-cycle: 38-649 pg/mL
Luteal Phase: 21-312 pg/mL
Postmenopausal: <29 pg/mL
Postmenopausal on HRT: <145 pg/mL

Male: 11 - 43 pg/mL

Female:
Estradiol, Follicular: 31 - 90 pg/mL
Estradiol, Ovulation: 60 - 533 pg/mL
Estradiol, Luteal: 60 - 232 pg/mL
Estradiol, Postmenopausal: < 5 - 138 pg/mL
Estradiol, 1st trimester: 154 - 3243 pg/mL
Estradiol, 2nd Trimester: 1561 - 21280 pg/mL
Estradiol, 3rd Trimester: 8525 - >30000 pg/mL

239

240

Coagulation Factors

241

09/07/22

Factor II

70-120 %

242

09/07/22

Factor V

70-120 %

243

09/07/22

Factor VII

55-170 %

244

Factor VIII

60-150 %

245

Factor IX

60-150 %

246

09/07/22

Factor X

70-120 %

247

09/07/22

Factor XI

60-150 %

248

Factor VIII Related Antigen (vWF Antigen)

> 49 %

249

250

Fecal Fat, Qualitative

Negative*

*Small amount of neutral fat is normal.

251

252

Fecal Lactoferrin

Negative

253

254

Fecal Occult Blood, Immunochemical

Negative

255

256

Ferritin

0 - 4 Days: No reference range established
4 - 14 Days: 100.0 - 717.0 ng/mL
15 - 180 Days: 14.0 - 647.0 ng/mL
6 - 11 Months: 8.0 - 182.0 ng/mL
1 - 4 Years: 5.0 - 100.0 ng/mL
5 - 13 Years: 14.0 - 79.0 ng/mL
14 - 15 Years:
Male: 13.0 - 83.0 ng/mL
Female: 6.0 - 67.0 ng/mL
16 - 19 Years:
Male: 11.0 - 172.0 ng/mL
Female: 6.0 - 67.0 ng/mL
>/= 20 Years:
Male: 22.0 - 275.0 ng/mL
Female: 5.0 - 204.0 ng/mL

0 - 30 Days: 150.0 - 973.0 ng/mL
1 - 5 Months: 8.5 - 580.0 ng/mL
6 Months - 14 Years: 14.0 - 101.0 ng/mL
15 - 19 Years:
Male: 20.9 - 173.0 ng/mL
Female: 3.9 - 114.0 ng/mL
>/=20 Years:
Male: 30.0 - 400.0 ng/mL
Female: 13.0 - 150.0 ng/mL

257

258

Fetal Fibronectin

Negative

259

260

Fetal Hgb Flow Marker

< 0 %

261

262

Fibrin Degradation Products (FDP)

< 5 ug/mL

263

264

Fibrinogen

240 - 490 mg/dL

265

266

Folate

7.0 - 31.4 ng/mL

4.8 - 24.2 ng/mL

267

268

Follicle-Stimulating Hormone (FSH)

Male:
1 - 11 Months: 0.1 - 2.4 mIU/mL
1 - 4 Years: 0.0 - 0.9 mIU/mL
5 - 9 Years: 0.0 - 1.6 mIU/mL
10 - 12 Years: 0.4 - 3.9 mIU/mL
13 - 18 Years: 0.8 - 5.1 mIU/mL
>/= 19 Years: 1.0 - 12.0 mIU/mL

Female:
1 - 11 Months: 0.4 - 10.4 mIU/mL
1 - 8 Years: 0.4 - 5.5 mIU/mL
9 - 10 Years: 0.4 - 4.2 mIU/mL
11 - 18 Years: 0.3 - 7.8 mIU/mL
>/= 18 Years:
Normally Menstruating Females:
Follicular Phase: 3.0 - 8.1 mIU/mL
Mid-Cycle: 2.6 - 16.7 mIU/mL
Luteal: 1.4 - 5.5 mIU/mL
Post Menopausal: 26.8 - 133.4 mIU/mL

Male:
0 - 11 Months: 0.1 - 3.2 mIU/mL
1 - 8 Years: 0.2 - 2.1 mIU/mL
9 - 11 Years: 0.4 - 4.2 mIU/mL
12 - 18 Years: 0.9 - 7.1 mIU/mL
>/= 19 Years: 1.5 - 12.4 mIU/mL

Female:
0 - 11 Months: 1.6 - 19.0 mIU/mL
1 - 8 Years: 0.7 - 5.8 mIU/mL
9 - 11 Years: 0.5 - 7.6 mIU/mL
12 - 18 Years: 0.9 - 9.1 mIU/mL
>/= 19 Years: 1.5 - 12.4 mIU/mL

269

270

Fractional Excretion of Sodium

<1.0% is indicative of prerenal azotemia.
>1.5% is indicative of acute tubular necrosis.

271

272

G-6-PD Screen

Normal

273

274

Gamma Glutamyltransferase (GGT)

Male: 12 - 64 IU/L
Female: 9 - 36 IU/L

Male: 8 - 61 IU/L
Female: 5 - 36 IU/L

275

276

Gentamicin

TROUGH:
0 - 2 Months < 1.1 ug/mL
>/= 3 Months < 2.0 ug/mL

PEAK:
5.0 - 10.0 ug/mL

RANDOM:
2.0 - 10.0 ug/mL

TROUGH:
0 - 2 Months: < 1.1 ug/mL
>/= 3 Months: < 2.0 ug/mL

PEAK:
5.0 - 10.0 ug/mL

RANDOM:
2.0 - 10.0 ug/mL

277

278

GI Panel by PCR

Not Detected

279

280

Giardia Antigen

Negative

281

282

Glomerular Filtration Rate (GFR)

>/= 2 Years: > 59 mL/min/1.73 m2*

*Interpret with caution, quantification of eGFR values below 60 mL/min/1.73 sq meter has more clinical implications for classification of kidney function than values above this level. GFR and GFRA are calculated using the CKD-EPI equation for >18 Years and Bedside Schwartz for 2-18 Years.

283

284

06/20/22

Gliadin Deamidated Peptide Ab, IgA EliA

< 7.0 U/mL

Interpretive Data:
Negative 0.1-6.9 U/mL
Equivocal 7.0-10.0 U/mL
Positive >10.0 U/mL

285

286

06/20/22

Gliadin Deamidated Peptide Ab, IgG EliA

< 7.0 U/mL

Interpretive Data:
Negative 0.4-6.9 U/mL
Equivocal 7.0-10.0 U/mL
Positive >10.0 U/mL

287

288

06/01/22

Glomerular Basement Membrane Antibody (GBM) EliA

< 7.0 U/mL

Normal < 7.0 U/mL
Equivocal 7.0-10.0 U/mL
Positive > 10.0 U/mL

289

290

Glucose:

291

Glucose, Serum

NICU Inpatient Locations: 51 - 60 mg/dL

0 - 23 Hours: 40 - 60 mg/dL
1 Day - 11 Months: 54 - 80 mg/dL
>/= 1 Year: 70 - 99 mg/dL

Interpretive Data:
Fasting Glucose:
Impaired Fasting 100 - 125 mg/dL
Diagnostic of Diabetes Mellitus >/= 126 mg/dL

Random Glucose:
Reference: 70 - 139 mg/dL
Diagnostic of Diabetes Mellitus >/= 200 mg/dL

292

Glucose, Post Prandial:

< 180 for Non-Pregnant Adults with Diabetes
</= 120 for Women with GDM

< 180 mg/dL for Non-Pregnant Adults with Diabetes
</= 120 mg/dL for Women with GDM

293

Glucose, 2 Hour Tolerance (non-gestational)

Fasting: 70 - 99 mg/dL
Interpretive Data:
70-99 Normal
100 - 125 Increased risk for Diabetes
>/= 126 Provisional Diagnosis of Diabetes

2 Hour: 70 - 139 mg/dL
Interpretive Data:
70-139 Normal
140-199 Increased risk for Diabetes
>/= 200 Provisional Diagnosis of Diabetes

Fasting: 70 - 99 mg/dL
Interpretive Data:
70-99 mg/dL Normal
100 - 125 mg/dL Increased risk for Diabetes
>/= 126 mg/dL Provisional Diagnosis of Diabetes

2 Hour: 70 - 139 mg/dL
Interpretive Data:
70-139 mg/dL Normal
140-199 mg/dL Increased risk for Diabetes
>/= 200 mg/dL Provisional Diagnosis of Diabetes

294

Glucose, Gestational Screen

70 - 139 mg/dL

295

Glucose, Gestational Tolerance

The diagnosis of Gestational Diabetes Mellitus is made if at least two of the following four plasma glucose levels are met or exceeded:
Fasting: < 95 mg/dL
1 Hour: < 180 mg/dL
2 Hour: < 155 mg/dL
3 Hour: < 140 mg/dL

296

Glucose, CSF

0-10 Years: 60-80 mg/dL
>/= 11 Years: 40-70 mg/dL

0 - 10 Years: 60-80 mg/dL
>/= 11 Years: 40-70 mg/dL

297

Glucose, Pleural Fluid

< 60 mg/dL is suggestive of an empyema or parapneumonic effusion.

298

Glucose, Estimated Average

Refer to Glucose

299

300

Group B Strep by Rapid PCR

Negative

301

302

Haptoglobin

0 - 14 Days: < 10 mg/dL
15 Days - 23 Months: 7 - 221 mg/dL
1 - 17 Years: 7 - 179 mg/dL
18 - 60 Years:
Male: 14 - 258 mg/dL
Female: 35 - 250 mg/dL
>/= 61 Years:
Male: 40 - 268 mg/dL
Female: 63 - 273 mg/dL

0 - 14 Days: </= 12 mg/dL
15 Days - 11 Months: </= 238 mg/dL
1 - 11 Years: </= 176 mg/dL
12 - 18 Years: </= 193 mg/dL
>/= 19 Years: 30 - 200 mg/dL

303

304

Hemoglobin A1C

< 5.7 %

Interpretive Data:
5.7 – 6.4% At Risk for Diabetes Mellitus

If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered.

>/= 6.5% Diagnostic for Diabetes Mellitus.
For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations.

< 5.7 %

Interpretive Data:
5.7 – 6.4 % At Risk for Diabetes Mellitus

If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered.

>/= 6.5 % Diagnostic for Diabetes Mellitus.
For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations.

305

306

Hemoglobin Electrophoresis

Hgb A1: 96.0 - 98.0 %
Hgb A2: 1.5 - 4.0 %
Hgb S: 0.0 %
Hgb C: 0.0 %
Other Hgb 1: 0.0 %
Hgb F:
0 - 6 Days: 77.0 - 97.0 %
7 - 14 Days: 79.6 - 91.4 %
15 - 45 Days: 59.8 - 89.6 %
46 Days - 2 Months: 23.9 - 67.2 %
3 - 5 Months: 4.4 - 27.5 %
6 - 8 Months: 1.5 - 27.8 %
9 - 14 Months: 0.4 - 8.4 %
15 - 23 Months: 0.1 - 4.9 %
2 - 5 Years: 0.0 - 3.7 %
6 - 17 Years: 0.0 - 1.3 %
>/= 18 Years: 0.0 %

307

308

Hemosiderin Laden Macrophage

Absent

309

310

Hepatitis A Antibody IgM

Non-Reactive

311

312

Hepatitis B Surface Antibody

< 8.00 mIU/mL: Non-Reactive - Individual is considered not immune to HBV infection.

>/= 8.00 to < 12.00 mIU/mL: Gray Zone - The immune status of the individual should be further assessed by considering other factors, such as clinical status, follow-up testing, associated risk factors, and the use of additional diagnostic information.

>/= 12.00 mIU/mL: Reactive - Individual is considered immune to HBV infection.

< 8.5 mIU/mL: Negative - Individual is considered to be not immune to infection with HBV.

>/= 8.5 to < 11.5 mIU/mL: Indeterminate - Unable to determine if anti-HBs is present at levels consistent with immunity.

>/= 11.5 mIU/mL: Positive - Anti HBs concentration detected at > 10 mIU/mL. Individual is considered to be immune to infection with HBV.

313

314

Hepatitis B Surface Antigen

Non-Reactive

315

316

Hepatitis B Core IgM

Non-Reactive

317

318

07/07/22

Hepatitis B Core Total Ab

Non-Reactive

319

07/07/22

320

Hepatitis C Antibody

Non-Reactive

321

322

Hepatitis C RNA by PCR, Quant

Not Detected

323

324

Herpes Simplex Virus (HSV), DNA by PCR

Not Detected

325

326

07/11/22

Herpes Simplex (HSV) Type 1 IgG

Negative

327

07/11/22

328

07/11/22

Herpes Simplex (HSV) Type 2 IgG

Negative

329

07/11/22

330

07/05/22

Herpes Simplex (HSV) I & II IgM

Negative

331

332

HIV Ag w/HIV1 & 2 Antibodies Screen

Non-Reactive

333

334

HIV Antibody

Non-Reactive

335

336

HIV Antigen

Non-Reactive

337

338

HIV-1 Viral Load RNA by PCR, Quantitative

Less than Limit of Dectection

339

340

07/07/22

Homocystine

Male: 5.5 - 16.2 umol/L
Female: 4.4 - 13.6 umol/L

341

07/07/22

342

Human Papillomavirus (HPV)

Negative

343

344

Immature Platelet Fraction (IPF)

1.1 - 6.1 %

345

346

Immunoglobulin A (IgA)

0 - 11 Months: 1 - 29 mg/dL
1 - 2 Years: 4 - 90 mg/dL
3 - 5 Years: 26 - 147 mg/dL
6 - 13 Years: 47 - 221 mg/dL
14 - 18 Years: 53 - 287 mg/dL
19 - 59 Years:
Male: 63 - 484 mg/dL
Female: 65 - 421 mg/dL
>/= 60 Years:
Male: 101 - 645 mg/dL
Female: 69 - 517 mg/dL

347

348

06/20/22

Immunoglobulin E (IgE)

0 - 5 Months: <14 kU/L
6 - 11 Months: < 35 kU/L
1 - 2 Years: < 98 kU/L
3 - 3 Years: < 200 kU/L
4 - 6 Years: < 308 kU/L
7 - 8 Years: < 404 kU/L
9 - 12 Years: < 697 kU/L
13 - 15 Years: < 630 kU/L
16 - 17 Years: < 538 kU/L
>/=18 Years: < 215 kU/L

349

350

Immunoglobulin G (IgG)

0 - 14 Days: 320 - 1407 mg/dL
15 Days - 11 Months: 109 - 702 mg/dL
1 - 3 Years: 316 - 1148 mg/dL
4 - 9 Years: 542 - 1358 mg/dL
10 - 19 Years: 658 - 1534 mg/dL
>/=20 Years:
Male: 540 - 1822 mg/dL
Female: 552 - 1631 mg/dL

0 - 14 Days: 320 - 1210 mg/dL
15 Days - 11 Months: 150 - 630 mg/dL
1 - 3 Years: 320 - 990 mg/dL
4 - 9 Years: 500 - 1170 mg/dL
10 - 18 Years: 600 - 1310 mg/dL
>/=19 Years: 700 - 1600 mg/dL

351

352

Immunoglobulin M (IgM)

0 - 14 Days: 5 - 35 mg/dL
15 Days - 2 Months 12 - 71 mg/dL
3 - 11 Months: 16 - 86 mg/dL
1 - 18 Years:
Male: 39 - 151 mg/dL
Female: 48 - 186 mg/dL
>/= 19 Years:
Male: 22 - 240 mg/dL
Female: 33 - 293 mg/dL

353

354

India Ink Prep

Negative

355

356

Influenza A/B PCR

Negative

357

358

Influenzae A & B Antigen Screen

Negative

359

360

07/07/22

Insulin, Fasting

3.0 - 19.0 uU/mL

361

07/07/22

362

Iron

0 - 13 Years 16 - 128 ug/dL
>/= 14 Years:
Male: 65 - 175 ug/dL
Female: 50 - 170 ug/dL

Female:
0 - 13 Years: 29 - 137 ug/dL
14 - 18 Years: 33 - 170 ug/dL
>/= 19 Years: 37 - 145 ug/dL

Male:
0 - 13 Years: 29 - 137 ug/dL
14 - 18 Years: 43 - 176 ug/dL
>/= 19 Years: 61 - 157 ug/dL

363

364

Iron Binding Capacity (TIBC), Calculated

0 - 62 Days: 130 - 280 ug/dL
63 Days - 11 Months: 134 - 405 ug/dL
1 - 59 Years:
Male: 218 - 455 ug/dL
Female: 225 - 478 ug/dL
>/= 60 Years:
Male: 204 - 569 ug/dL
Female: 216 - 450 ug/dL

0 - 56 Days: 139 - 304 ug/dL
57 Days - 11 Months: 144 - 440 ug/dL
1 - 17 Years: 298 - 458 ug/dL
>/= 18 Years: 250 - 450 ug/dL

365

366

Kleihauer-Betke (KB) Stain

</= 0.10

367

368

Lactate Dehydrogenase (LDH)

SERUM:
0 - 14 Days: 309 - 1222 IU/L
15 Days - 11 Months: 163 - 452 IU/L
1 - 9 Years: 192 - 321 IU/L
10 - 14 Years:
Male: 170 - 283 IU/L
Female: 157 - 272 IU/L
15 - 18 Years: 130 - 250 IU/L
>/= 19 Years: 125 - 220 IU/L

BODY FLUID:
Interpretive Data:
Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein >0.6 is predictive of an exudate.

0 - 14 Days: </= 1128 IU/L
15 Days - 11 Months: </= 424 IU/L
1 - 9 Years: </= 305 IU/L
10 - 14 Years:
Male: </= 270 IU/L
Female: </= 260 IU/L
15 - 18 Years: </= 240 IU/L
>/= 19 Years:
Male: 135 - 225 IU/L
Female: 135 - 214 IU/L

BODY FLUID:
Interpretive Data:
Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein >0.6 is predictive of an exudate.

369

370

Lactic Acid

PLASMA:
0.5 - 2.2 mmol/L

CSF:
0.6 - 2.2 mmol/L

PLASMA:
0.5 - 2.2 mmol/L

CSF:
0 - 2 Days: 1.1 - 6.7 mmol/L
3 - 10 Days: 1.1 - 4.4 mmol/L
11 Days - 18 Years: 1.1 - 2.8 mmol/L
>/= 19 Years: 1.1 - 2.4 mmol/L

371

372

Legionella Antigen, Urine

Negative

373

374

Levetracitam (Keppra)

5.0 - 45.0 ug/mL

375

376

Lipase

0 - 18 Years: 0 - 39 IU/L
>/= 19 Years: 8 - 78 IU/L

0 - 18 Years: </= 39 IU/L
>/= 19 Years: 13 - 60 IU/L

377

378

Lipid Laden Macrophage

Negative

379

380

Lipid Panel

Refer to ACC/AHA Clinical Practice Guidelines

381

Cholesterol

0 - 14 Days: 42 - 125 mg/dL
15 Days - 11 Months: 64 - 237 mg/dL
1 - 9 Years: 112 - 208 mg/dL
10 - 19 Years:
Acceptable < 170 mg/dL
Borderline 170 - 199 mg/dL
Abnormal >/=200 mg/dL
>/= 20 Years:
Desirable: < 200 mg/dL
Borderline High: 200-239 mg/dL
High: >/= 240 mg/dL

0 - 14 Days:
Male: 44 - 109 mg/dL
Female: 48 - 125 mg/dL
15 Days - 11 Months: 66 - 234 mg/dL
1 - 9 Years: 112 - 207 mg/dL
10 - 19 Years: < 170 mg/dL
>/= 20 Years: < 200 mg/dL

382

Cholesterol/HDL Ratio

< 3.5

383

HDL

0 - 15 Days: 15 - 42 mg/dL
15 Days - 1 Year: 12 - 71 mg/dL
1 - 10 Years: 32 - 73 mg/dL
10 - 19 Years:
Acceptable: > 45 mg/dL
Borderline: 40 - 45 mg/dL
Abnormal: < 40 mg/dL
>/= 20 Years:
Optimal: >/= 60 mg/dL
Borderline: 40 - 59 mg/dL
Major Risk Factor: < 40 mg/dL

0 - 14 Days: 7 - 39 mg/dL
15 Days - 11 Months: </=75 mg/dL
1 - 3 Years: 28 - 65 mg/dL
4 - 9 Years: 31 - 77 mg/dL
10 - 19 Years:
Acceptable: > 45 mg/dL
Borderline: 40 - 45 mg/dL
Abnormal: < 40 mg/dL
>/= 20 Years:
Optimal: >/= 60 mg/dL
Borderline: 40 - 59 mg/dL
Major Risk Factor: < 40 mg/dL

384

LDL

0 - 11 Months: 13 - 173 mg/dL
1 - 9 Years: 47 - 128 mg/dL
10 - 19 Years:
Acceptable: < 110 mg/dL
Borderline: 110 - 129 mg/dL
High: >/=130 mg/dL
>/=20 Years:
Desirable: <130 mg/dL
Borderline: 130 - 159 mg/dL
High Risk: >/=160 mg/dL

385

Non-HDL Cholesterol

0 - 11 Months: 28 - 202 mg/dL
1 - 9 Years: 69 - 166 mg/dL
10 - 19 Years:
Acceptable: < 120 mg/dL
Borderline: 120 - 144 mg/dL
High: >/= 145 mg/dL
>/= 20 Years:
Optimal: < 130 mg/dL
Borderline High: 130 - 159 mg/dL
High: 160 - 189 mg/dL
Very High: > 190 mg/dL

386

Triglycerides

0 - 9 Years:
Acceptable < 75 mg/dL
Borderline 75 - 99 mg/dL
Abnormal: >/= 100 mg/dL
10 - 19 Years:
Acceptable: < 90 mg/dL
Borderline: 90 - 129 mg/dL
Abnormal: >/= 130 mg/dL
>/= 20 Years:
Acceptable: < 150 mg/dL
Borderline: 150 - 199 mg/dL
High: 200 - 499 mg/dL
Very High: >/= 500 mg/dL

387

VLDL

< 40 mg/dL

388

389

Lithium

0.6 - 1.2 mmol/L

390

391

Low Molecular Weight Heparin (LMWH)

Once daily dosing: 1.00 - 2.00 IU/mL
Twice daily dosing: 0.60 - 1.00 IU/mL
Prophylactic range: 0.20 - 0.50 IU/mL

392

393

Luteinizing Hormone (LH)

Female:
4 Days - 2 Months: 0.0 - 2.4 mIU/mL
3 - 11 Months: 0.0 - 1.2 mIU/mL
1 - 9 Years: 0.0 - 0.3 mIU/mL
10 - 12 Years: 0.0 - 4.3 mIU/mL
13 - 14 Years: 0.4 - 6.5 mIU/mL
15 - 16 Years: 0.0 - 13.1 mIU/mL
17 - 18 Years: 0.0 - 8.4 mIU/mL
Interpretive Data:
Normal Menstruating Females:
Follicular Phase: 1.8 - 11.8 mIU/mL
Mid-Cycle Peak: 7.6 - 89.1 mIU/mL
Luteal Cycle: 0.6 - 14.0 mIU/mL
Postmenopausal without Hormone Therapy: 5.16 - 61.99 mIU/mL

Male:
4 Days - 2 Months: 0.2 - 3.8 mIU/mL
3 - 1 Months: 0.0 - 2.9 mIU/mL
1 - 9 Years: 0.0 - 0.3 mIU/mL
10 - 12 Years: 0.0 - 4.3 mIU/mL
13 - 14 Years: 0.0 - 4.1 mIU/mL
15 - 16 Years: 0.8 - 4.8 mIU/mL
17 - 18 Years: 0.9 - 7.1 mIU/mL
>/= 19 Years: 0.6 - 12.1 mIU/mL

Male:
0 - 5 Months: </= 6.2 mIU/mL
6 Months - 10 Years: </= 1.3 mIU/mL
11 - 13 Years: </= 2 mIU/mL
14 - 18 Years: 1.3 - 8.4 mIU/mL
>/= 19 Years: 1.7 - 8.6 mIU/mL

Female:
0 - 5 Months: </=8.2 mIU/mL
6 Months - 10 Years: </=1.3 mIU/mL
11 - 13 Years: </=10 mIU/mL
14 - 18 Years: 0.4-25 mIU/mL
>/= 19 Years:
Mid-Cycle/Ovulation: 14 - 95.6 mIU/mL
Luteal: 1 - 11.4 mIU/mL
Postmenopausal (w/o Hormone Therapy): 7.7 - 58.5 mIU/mL

394

395

Magnesium

0 - 20 Years: 1.5 - 2.3 mg/dL
>/= 21 Years: 1.6 - 2.6 mg/dL

396

397

Malaria

Screan: Negative

% Parasitemia: 0 %

398

399

Meningitis/Enchephalitis Panel by PCR, CSF

Not Detected

400

401

Methicillin-resistant staphylococcus aureus (MRSA) PCR

Negative

402

403

Methotrexate Level

Interpretive Data:
Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors.

24 hr: 5-10 umol/L
48 hr: 0.5-1.0 umol/L
72 hr: <0.2 umol/L

Interpretive Data:
Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors.

24 hr: 5 - 10 umol/L
48 hr: 0.5 - 1.0 umol/L
72 hr: < 0.2 umol/L

404

405

Microalbumin, Urine

RANDOM:
< 30 mg/L

TIMED:
Output:
Reference: < 30 mg/24hr
Interpretive Data:
Normal: < 30 mg/24hr
Microalbuminuria: 30 - 299 mg/24hr
Macro clinical albuminuria: >/= 300 mg/24hr

Concentration:
Reference: < 20 ug/min
Interpretive Data:
Normal: < 20 ug/min
Microalbuminuria: 20 - 199 ug/min
Macro clinical albuminuria: >/= 200 ug/min

406

407

Microalbumin/Creatinine Ratio, Urine

< 30 mg/g

Interpretive Data:
Normal to Mildly Increased: < 30 mg/g
Moderately Increased: 30 - 299 mg/g
Severely Increased: >/= 300 mg/g

Two of three specimens of microalbumin/creatinine ratio should be abnormal before considering a patient to have high or very high albuminuria.

408

409

Monotest

Negative

410

411

06/01/22

Myeloperoxidase IgG (MPO) Antibody

< 3.5 U/mL

Interpretive Data:
< 3.5 Normal
3.5-5.0 Equivocal
> 5.0 Positive

The specificity of anti-MPO for systemic vasculitis and/or idiopathic crescentic glomerulonephritis is as high as 95% when groups of patients with renal disorders and diseases related to vasculitis are studied. However, MPO antibodies occur incidentally in other diseases such as drug induced lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease.

412

413

Mycobacterium Tuberculosis by PCR

Not Detected

414

415

Mycoplasma pneumonia DNA

Not Detected

416

417

09/06/22

Myoglobin

Male: < 93 ng/mL
Female: < 81 ng/mL

418

09/06/22

419

Neisseria gonorrhoeae (GC), NAAT

Negative

420

421

Occult Blood, Fecal/Gastric/Vomitus

Negative

422

423

Osmolality

SERUM:
270 - 295 mOsm/kgH2O

URINE:
50 - 1200 mOsm/kgH2O

Interpretive Data:
Varies significantly with hydration
Average fluid intake 300 - 900
After 12 Hr fluid restriction > 850

424

425

Parathyroid Hormone (PTH), Intact

ABBOTT: 9 - 77 pg/mL

ROCHE: 15 - 65 pg/mL

15 - 72 pg/mL

426

427

Parathyroid Hormone (PTH), Baseline

ABBOTT: 9 - 77 pg/mL

ROCHE: 15 - 65 pg/mL

15 - 72 pg/mL

428

429

Parathyroid Hormone (PTH) Intraoperative

<50% of baseline value

Interpretive Data:
< 50 % of baseline value
This assay has not been clinically validated for intraoperative use, however intraoperative measurements were included in assay validations performed by Abbott.

430

431

Phenobarbital Therapeutic Range

15 - 40 ug/mL

432

433

Phosphorus

0 - 14 Days: 5.6 - 10.5 mg/dL
15 Days - 11 Months: 4.8 - 8.4 mg/dL
1 - 4 Years: 4.3 - 6.8 mg/dL
5 - 12 Years: 4.1 - 5.9 mg/dL
13 - 15 Years:
Male: 3.5 - 6.2 mg/dL
Female: 3.2 - 5.5 mg/dL
16 - 18 Years: 2.9 - 5.0 mg/dL
>/=19 Years: 2.3 - 4.7 mg/dL

0 - 14 Days: 5.3 - 9.8 mg/dL
15 Days - 11 Months: 4.6 - 7.9 mg/dL
1 - 4 Years: 4.1 - 6.4 mg/dL
5 - 12 Years: 4.0 - 5.6 mg/dL
13 - 15 Years:
Male: 3.5 - 5.8 mg/dL
Female: 3.1 - 5.3 mg/dL
16 - 18 Years: 2.9 - 4.8 mg/dL
>/=19 Years: 2.5 - 4.5 mg/dL

434

435

Pinworm Prep/Exam

Not Present

436

437

Platelet Function Screen (PFS)

ASPIRIN: 350 - 549 sec

P2Y12: 50 - 208 sec

SCREEN:
Col/Epi: 78 - 177 sec
Col/ADP: 50 – 102 sec

438

439

Post Vasectomy Semen Analysis

Post Vas Total Sperm: Absent
Post Vas Semen Volume: 0.5 - 5.0 mL
Post Vas Nonmotile Sperm: < 1%
Post Vas Motile Sperm: < 1%

440

441

Potassium (K+)

SERUM/PLASMA:
0 - 27 Days: 3.7 - 5.9 mmol/L
28 Days - 1 Year: 4.1 - 5.3 mmol/L
2 - 17 Years: 3.4 - 4.7 mmol/L
>/= 18 Years: 3.5 - 5.1 mmol/L

URINE:
Random:
Interpretive Data: No Reference Ranges Established

Timed:
25.0 - 125.0 mmol/24 hr
Interpretive Data: Varies significantly with hydration and diet.

442

443

Prealbumin

0 - 11 Months: 7.0 - 25.0 mg/dL
1 - 11 Years: 11 - 34.0 mg/dL
>/= 12 Years: 14.0 - 45.0 mg/dL

0 - 14 Days: </= 1.0 mg/dL
15 Days - 11 Months: 4.0 - 24.0 mg/dL
1 - 4 Years: 11.0 - 23.0 mg/dL
5 - 12 Years: 13.0 - 26.0 mg/dL
13 - 15 Years: 17.0 - 31.0 mg/dL
16 - 17 Years:
Female: 16.0 - 33.0 mg/dL
Male: 20.0 - 35.0 mg/dL
>/= 18 Years: 20.0 - 40.0 mg/dL

444

445

Procalcitonin

< 0.10 ng/mL

Interpretive Data:
< 0.5: On the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock
> 2.0: On the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock

Procalcitonin values are physiologically increased in neonates during the first two Days of life. The reference range applies from three Days after birth.

446

447

Progesterone

Male: < 0.3 ng/mL

Normal Menstruating Females:
Follicular Phase: < 0.4 ng/mL
Luteal Phase: 1.2 - 15.9 ng/mL

Postmenopausal Females: <0.3 ng/mL

Pregnant Females:
First Trimester: 2.8 - 147.3 ng/mL
Second Trimester: 22.5 - 95.3 ng/mL
Third Trimester: 27.9 - 242.5 ng/mL

Male: < 0.2 ng/mL

Female:
Cycle Phase:
Follicular: < 0.2 ng/mL
Ovulation: 0.2 - 4.1 ng/mL
Luteal: 4.1 - 14.5 ng/mL
Menopausal: < 0.2 ng/mL
Healthy Pregnant Females:
1st Trimester: 11.0 - 44.3 ng/mL
2nd Trimester: 25.4 - 83.4 ng/mL
3rd Trimester: 58.7 - 214.0 ng/mL

448

449

Prolactin

4 - 29 Days: 12.6 - 213.0 ng/mL
30 Days - 11 Months: 6.3 - 114.0 ng/mL
1 - 18 Years: 4.2 - 23.0 ng/mL
>/= 19 Years:
Male: 3.5 - 19.4 ng/mL
Female: 5.2 - 26.5 ng/mL

0 - 30 Days: 1.1 - 470.0 ng/mL
1 - 11 Months: 5.2 - 60.0 ng/mL
1 - 18 Years: 3.0 - 25.0 ng/mL
>/= 19 Years:
Male: 4.0 - 15.2 ng/mL
Female (Non-Pregnant): 4.79 - 23.3 ng/mL

450

451

09/07/22

Protein C Activity

70 - 161 %

452

09/07/22

453

09/07/22

Protein S Activity

70 - 140 %

454

09/07/22

455

Protein, Total

SERUM:
0 - 14 Days: 5.3 - 8.3 g/dL
15 Days - 11 Months: 4.4 - 7.1 g/dL
1 - 5 Years: 6.1 - 7.5 g/dL
6 - 8 Years: 6.4 - 7.7 g/dL
9 - 18 Years: 6.5 - 8.1 g/dL
>/= 19 Years: 6.2 - 8.3 g/dL

URINE:
Random: 10 - 140 mg/L

Timed: < 300 mg/24 hr
At Rest 50 - 80 mg/24 hr

BODY FLUID:
Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate.

CSF:
0 - 30 Days: 20.0 - 80.0 mg/dL
>/= 1 Month: 15.0 - 45.0 mg/dL

SERUM:
0 -14 Days: 5.1 - 8.0 g/dL
15 Days - 11 Months: 4.3 - 6.9 g/dL
1 - 5 Years: 5.9 - 7.3 g/dL
6 - 8 Years: 6.2 - 7.5 g/dL
9 - 18 Years: 6.3 - 7.8 g/dL
>/=19 Years: 6.4 - 8.3 g/dL

URINE:
Concentration: No Established Reference Range

Timed: < 300 mg/24 hr
At Rest 50 - 80 mg/24 hr

BODY FLUID:
Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate.

CSF:
0 - 30 Days: 20.0 - 80.0 mg/dL
>/= 1 Month: 15.0 - 45.0 mg/dL

456

457

Protein/Creatinine Ratio, Urine

< 0.2 mg/mg

458

459

Protein Electrophoresis, Serum

Albumin: 3.00 - 5.05 g/dL
Alpha 1 Globulin: 0.13 - 0.36 g/dL
Alpha 2 Globulin: 0.57 - 1.22 g/dL
Beta: 0.69 - 1.33 g/dL
Gamma Globulin: 0.63 - 2.00 g/dL
Alb/Glob Ratio: 0.92 - 1.86

460

461

Prothrombin Time (PT)/INR

PT: 11.8 - 15.0 seconds

INR: 0.8 - 1.2

462

463

09/07/22

PT Mixing Study

No Inhibitor Detected

464

09/07/22

465

Partial Thromboplastin Time (PTT)

24 - 36 seconds

466

467

09/07/22

PTT Mixing Study

No Inhibitor Detected

468

09/07/22

469

PSA

TOTAL: < 4.1 ng/mL

470

471

06/27/22

Quantiferon TB Plus

Negative

472

473

Respiratory Panel by PCR

474

Adenovirus

Not Detected

475

Bordetella Pertussis

Not Detected

476

Bordetella Parapertussis

Not Detected

477

Chlamydophilia Pneumoniae

Not Detected

478

Coronavirus 229E

Not Detected

479

Coronavirus HKU1

Not Detected

480

Coronavirus NL63

Not Detected

481

Coronavirus OC43

Not Detected

482

Coronavirus SARS-CoV-2

Not Detected

483

Human Metapneumovirus

Not Detected

484

Human Resp Syncytial Virus

Not Detected

485

Influenza Virus A

Not Detected

486

Influenza A/H1 2009

Not Detected

487

Influenza A/H1

Not Detected

488

Influenza A/H3

Not Detected

489

Influenza Virus B

Not Detected

490

Mycoplasma Pneumoniae

Not Detected

491

Parainfluenza Virus 1

Not Detected

492

Parainfluenza Virus 2

Not Detected

493

Parainfluenza Virus 3

Not Detected

494

Parainfluenza Virus 4

Not Detected

495

Rhino/Entero

Not Detected

496

497

Respiratory Syncytial Virus (RSV) Antigen

Negative

498

499

Reticulocyte Count (Automated)

RELATIVE
0 - 3 Days: 3.47 - 5.40 %
4 - 30 Days: 1.06 - 2.37 %
31 - 60 Days: 2.12 - 3.47 %
61 Days - 5 Months: 1.55 - 2.70 %
6 Months - 1 Year: 0.99 - 1.82 %
2 - 5 Years: 0.82 - 1.45 %
6 - 11 Years: 0.98 - 1.94 %
12 - 17 Years: 0.90 - 1.49 %
>/= 18 Years:
Male: 0.51 - 1.81 %
Female: 0.50 - 1.70 %

ABSOLUTE
0 - 3 Days: 0.15 - 0.22 Mil/uL
4 - 30 Days: 0.05 - 0.11 Mil/uL
31 - 60 Days: 0.05 - 0.08 Mil/uL
61 Days - 5 Months: 0.05 - 0.09 Mil/uL
6 Months - 1 Year: 0.04 - 0.11 Mil/uL
2 - 18 Years: 0.04 - 0.07 Mil/uL
>/= 18 Years:
Male: 0.03 - 0.01 Mil/uL
Female: 0.02 - 0.08 Mil/uL

IRF
1 - 3 Days: 30.50 - 35.10 %
4 - 30 Days: 14.50 - 24.60 %
31 - 60 Days: 19.10 - 28.90 %
2 - 5 Months: 13.40 - 23.30 %
6 - 23 Months: 11.40 - 25.80 %
2 - 5 Years: 8.40 - 21.70 %
6 - 11 Years: 8.90 - 24.10 %
12 - 17 Years: 9.00 - 18.70 %
>/= 18 Years:
Male: 9.30 - 17.40 %
Female: 2.30 - 13.40 %

HEMOGLOBIN EQUIVALENT
Male:
0 - 5 Months: 27.6 - 38.7 pg
6 - 23 Months: 28.7 - 35.7 pg
2 - 5 Years: 27.7 - 37.8 pg
6 - 11 Years: 32.4 - 37.6 pg
12 - 17 Years: 30.3 - 40.4 pg
>/= 18 Years: 36.0 - 38.6 pg
Female:
0 - 5 Months: 29.2 - 37.5 pg
6 - 23 Months: 30.1 - 35.7 pg
2 - 5 Years: 29.3 - 37.3 pg
6 - 11 Years: 30.4 - 39.7 pg
12 - 17 Years: 29.9 - 38.4 pg
>/= 18 Years: 30.6 - 40.7 pg

500

501

Rheumatoid Factor (RF)

< 30 IU/mL

< 14 IU/mL

502

503

Rotavirus Antigen

Negative

504

505

Strep Group A Screen

Negative

506

507

Salicylate

< 30 mg/dL

508

509

06/01/22

Serine Protease 3 (PR-3) Antibody

< 2.0 U/mL

Interpretive Data:
< 2.0 Normal
2.0-3.0 Equivocal
> 3.0 Positive

Anti-PR3 antibodies are highly specific for GPA. However, PR3 antibodies are reported in infective disorders in monoclonal gammopathy and in a few cases of malignancy without signs of secondary vasculitis.

510

511

07/07/22

Sex Hormone Binding Globulin (SHBG)

Male: 11.2 - 78.1 nmol/L
Female: 11.7 - 137.2 nmol/L

512

07/07/22

513

Sickle Cell Screen

Negative

514

515

Sirolimus

5.0 - 15.0 ng/mL

This assay is not performed on Roche analyzers.

516

517

Sodium

SERUM:
0 - 26 Days: 133 - 146 mmol/L
27 - 1 Year: 139 - 146 mmol/L
2 - 17 Years: 138 - 145 mmol/L
>/= 18 Years 136 - 145 mmol/L

URINE:
Random: No reference ranges established.

Timed:
Male:
6 - 10 Years: 41 - 115 mmol/24hr
10 - 14 Years 63 - 177 mmol/24hr
>/= 14 Years: 40 - 220 mmol/24hr
Female:
6 - 10 Years: 20 - 69 mmol/24hr
10 - 14 Years 48 - 168 mmol/24hr
>/= 14 Years: 40 - 220 mmol/24hr

Interpretive Data: Varies significantly with hydration and diet.

518

519

Special Fungal/Pneumocystis Stain

Negative

520

521

Strep pneumoniae Antigen, Urine/CSF

Negative

522

523

Syphilis Testing

524

Treponema Antibody

Non-Reactive

525

Rapid Plasma Reagin (RPR)

Non-Reactive

526

Treponema Particle Agglutination

Non-Reactive

527

07/18/22

VDRL, CSF

Non-Reactive

528

529

09/06/22

T3, Free

Male and Female:
4 Days - 11 Months: 2.32 - 4.87 pg/mL
1 - 11 Years: 2.79 - 4.42 pg/mL
12 - 14 Years:
Male: 2.89 - 4.33 pg/mL
Female: 2.50 - 3.95 pg/mL
15 - 18 Years:
Male: 2.25 - 3.85 pg/mL
Female: 2.31 - 3.71 pg/mL
>/= 19 Years: 1.71 - 3.71 pg/mL

530

09/06/22

531

09/06/22

T3, Total

4 Days - 11 Months: 85 - 234 ng/dL
1 - 11 Years: 113 - 189 ng/dL
12 - 14 Years: 98 - 176 ng/dL
15 - 16 Years: 93 - 156 ng/dL
17 - 18 Years: 90 -168 ng/dL
>/= 19 Years: 58 - 159 ng/dL

532

09/06/22

533

T4, Free

0 - 11 Months:
Male: 0.90-1.80 ng/dL
Female: 0.90-1.60 ng/dL
1 - 10 Years: 0.80-1.60 ng/dL
11 - 20 Years: 0.80-1.40 ng/dL
>/= 21 Years: 0.70-1.50 ng/dL

0 - 30 Days: 1.24 - 3.89 ng/dL
1 - 11 Months: 1.09 - 1.71 ng/dL
1 - 18 Years: 1.01 - 1.63 ng/dL
>/= 19 Years: 0.93 - 1.70 ng/dL

534

535

07/07/22

T4, Total

4.87 - 11.72 ug/dL

536

07/07/22

537

Tacrolimas (FK506)

5.0 - 20.0 ng/mL

538

539

Thromboelastogram (TEG)

540

TEG, Basic

R Plain 5.0 - 10.0 min
K Plain 1.0 - 3.0 min
Angle Plain 53.0 - 72.0 deg
MA Plain 50.0 - 70.0 mm
LY30 Plain 0.0 - 8.0 %
R Heparin Treated 5.0 - 10.0 min
K Heparin Treated 1.0 - 3.0 min
Angle Heparin Treated 53.0 - 72.0 deg
MA Heparin Treated 50.0 - 70.0 mm
LY30 Heparin Treated 0.0 - 8.0 %

541

TEG, Accelerated

R Rapid Plain 0.4 - 0.7 min
K Rapid Plain 0.6 - 2.3 min
Angle Rapid Plain 64.0 - 80.0 deg
MA Rapid Plain 52.0 - 71.0 mm
LY30 Rapid Plain 0.0 - 8.0 %
TEG ACT Plain 86.0 - 118.0 sec
R Rapid Heparin Treated 0.4 - 0.7 min
K Rapid Heparin Treated 0.6 - 2.3 min
Angle Rapid Heparin Treated 64.0 - 80.0 deg
MA Rapid Heparin Treated 52.0 - 71.0 mm
LY30 Rapid Heparin Treated 0.0 - 8.0 %
TEG ACT Heparin Treated 86.0 - 118.0 sec

542

TEG with Platelet Mapping

543

TEG Functional Fibrinogen

MA Functional Fibrinogen 11.5 - 31.6 mm
TEG Functional Fibrinogen 210.6 - 576.4 mg/dL

544

TEG Global Hemostasis

R-TEG 4.6 - 9.1 minutes
K-TEG 0.8 - 2.1 minutes
Angle-TEG 63.0 - 78.0 degrees
MA-TEG 52.0 - 69.0 mm
MA-TEG, Rapid 52.0 - 70.0 mm
R-TEG, w/Hep 4.3 - 8.3 minutes
MA Functional Fibrinogen 15.0 - 32.0 mm
FLEV 278.0 - 581.0 mg/dL

545

TEG Global Hemostasis w Lysis

R-TEG 4.6 - 9.1 minutes
MA-TEG, Rapid 52.0 - 70.0 mm
MA Functional Fibrinogen 15.0 - 32.0 mm
LY30-TEG <= 2.6 %

546

547

09/06/22

Testosterone

Male:
21 - 49 Years: 240 - 871 ng/dL
>/= 50 Years: 221 - 716 ng/dL

Female:
Premenopausal 21 - 49 Years: 14 - 53 ng/dL
Postmenopausal >/= 50 Years: 12 - 36 ng/dL

548

09/06/22

549

07/07/22

Theophylline

5 - 20 ug/mL

550

07/07/22

551

09/07/22

Thrombin Clot Time

13.0 - 21.0 seconds

552

09/07/22

553

07/07/22

Thyroglobulin Antibody

< 4.1 IU/mL

554

07/07/22

555

07/07/22

Thyroid Peroxidase Autoantibodies (TPO)

< 5.6 IU/mL

556

07/07/22

557

06/01/22

Tissue Transglutaminase (TTG), IgA

< 7.0 EliA u/mL

Interpretive Data:
0.1-6.9: Negative
7.0-10.0: Equivocal
>1 0.0: Positive

558

559

Tobramycin

TROUGH:
0 - 2 Months < 1.1 ug/mL
>/= 3 Months < 2.0 ug/mL

PEAK:
5.0 - 10.0 ug/mL

RANDOM:
2.0 - 10.0 ug/mL

560

561

07/11/22

Toxoplasma IgG

Negative

562

07/11/22

563

Transferrin

0 - 62 Days: 104 - 224 mg/dL
63 Days - 11 Months: 107 - 324 mg/dL
1 - 59 Years:
Male: 174 - 364 mg/dL
Female: 180 - 382 mg/dL
>/= 60 Years:
Male:163 - 344 mg/dL
Female:173 - 360 mg/dL

0 - 56 Days: 111 - 243 mg/dL
57 Days - 11 Months: 115 - 352 mg/dL
1 - 17 Years: 238 - 366 mg/dL
>/= 18 Years 200 - 360 mg/dL

564

565

Transferrin Saturation

Male: 20 - 50 %
Female: 15 - 50 %

566

567

Trichomonas Vaginalis, NAAT

Negative

568

569

Troponin

< 0.03 ng/mL

570

571

Thyroid Stimulating Hormone (TSH)

4 Days - 5 Months: 0.730 - 4.770 uIU/mL
6 Months - 13 Years: 0.700 - 4.170 uIU/mL
14 - 18 Years: 0.470 - 3.410 uIU/mL
>/= 19 Years: 0.350 - 4.940 uIU/mL

0 - 30 Days: 1.230 - 27.200 uIU/ml
1 - 11 Months: 1.030 - 6.800 uIU/ml
1 - 14 Years: 1.120 - 5.010 uIU/ml
15 - 18 Years: 0.680 - 4.090 uIU/ml
>/= 19 Years: 0.270 - 4.200 uIU/ml

572

573

Total Volume, Urine

Varies significantly with hydration.

0 - 2 Days: 30-60 mL/24 hr
3 - 9 Days: 100-300 mL/24 hr
10 Days - 1 Month: 250-450 mL/24 hr
2 - 11 Months: 400-500 mL/24 hr
1 - 2 Years: 500-600 mL/24 hr
3 - 4 Years: 600-700 mL/24 hr
5 - 7 Years: 650-1000 mL/24 hr
8 - 14 Years: 800-1400 mL/24 hr
15 - 59 Years:
Male: 800-1800 mL/24 hr
Female: 600-1600 mL/24 hr
>/= 60 Years: 250-2400 mL/24 hr

574

575

Unfractionated Heparin Anti-Xa (UFH)

0.30 - 0.70 IU/mL

576

577

Urea Nitrogen

BLOOD (BUN):
Male:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
10 - 18 Years: 7 - 20 mg/dL
19 - 49 Years: 9 - 21 mg/dL
>/= 50 Years: 8 - 26 mg/dL

Female:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
>/= 10 Years: 7 - 20 mg/dL

URINE:
Random: No Reference Ranges Established

Timed:
3,000-5,000 mg/6 Hrs
12,000 - 20,000 mg/24 Hrs

BLOOD (BUN)
0 - 7 Days: 3 - 25 mg/dL
8 Days - 11 Months: 4 - 19 mg/dL
1 - 18 Years: 5 - 18mg/dL
19 - 59 Years: 6 - 20 mg/dL
60 - 90 Years: 8 - 23 mg/dL
>/= 91 Years: 10 - 31 mg/dL

URINE:
Random: No Reference Ranges Established

Timed:
3,000-5,000 mg/6 Hrs
12,000 - 20,000 mg/24 Hrs

578

579

Uric Acid

0 - 14 Days: 2.8 - 12.0 mg/dL
15 Days - 11 Months: 1.6 - 6.3 mg/dL
1 - 11 Years: 1.8 - 4.9 mg/dL
12 - 18 Years:
Male: 2.6 - 7.6 mg/dL
Female: 2.6 - 5.9 mg/dL
>/= 19 Years:
Male: 3.5 - 7.2 mg/dL
Female: 2.6 - 6.0 mg/dL

0 - 14 Days: 2.7 - 12.0 mg/dL
15 Days - 11 Months: 1.5 - 6.2 mg/dL
1 - 11 Years: 1.7 - 4.7 mg/dL
12 - 18 Years:
Female: 2.5 - 5.7 mg/dL
Male: 2.5 - 7.5 mg/dL
>/= 19 Years:
Male: 3.4 - 7.0 mg/dL
Female: 2.4 - 5.7 mg/dL

580

581

Urinalysis

582

Urinalysis Chem Screen

583

Appearance

Clear, Slightly Hazy, Hazy

584

Spec Gravity

1.003 - 1.035

585

4.6 - 8.0

586

Glucose

Negative

587

Protein

Negative

588

Ketone

Negative

589

Bilirubin

Negative

590

Blood

Negative

591

Nitrite

Negative

592

Urobilinogen

< 2.0 mg/dL

593

Leuk Esterase

Negative

594

Urinalysis Microscopic Exam

595

WBC’s

0 - 5 /HPF

596

RBC’s

0 - 2 /HPF

597

Epithelial Cells (Squamous)

</= 8 /LPF

598

Renal Epithelial Cells

0 /LPF

599

Bacteria

< Moderate

600

Hyaline Casts

0 - 3 /LPF

601

Cast

0 /LPF

602

603

Vaginitis Panel by PCR

604

Trichomonas

Negative

605

Gardnerella

Negative

606

Candida

Negative

607

608

Valproic Acid

TOTAL: 50 - 125 ug/mL

FREE: 6 - 22 ug/mL

FREE %: 5 - 18 %

609

610

Vancomycin

TROUGH:
10.0 - 20.0 ug/mL

PEAK:
30.0 - 50.0 ug/mL

RANDOM:
5.0 - 40.0 ug/mL

611

612

07/05/22

Varicella Zoster, IgM

Negative

613

614

Vitamin B12

213 - 816 pg/mL

232 - 1245 pg/mL

615

616

09/06/22

Vitamin D 25-Hydroxy

30 - 100 ng/mL

Interpretive Data:
< 20: Deficiency
20-29: Insufficiency
30-100: Sufficiency
> 150: Possible Toxicity

617

09/06/22

618

Wet Prep (Manual)

None Seen/Not Present

619

620

POINT OF CARE:

621

ACT-celite

74 - 152 seconds

622

623

ACT-Kaolin

74 - 152 seconds

624

625

BUN

Male:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
10 - 18 Years: 7 - 20 mg/dL
19 - 49 Years: 9 - 21 mg/dL
>/= 50 Years 8 - 26 mg/dL

Female:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
>/= 10 Years: 7 - 20 mg/dL

626

627

Chloride

0 - 29 Days: 98 - 113 mmol/L
>/= 30 Days: 98 - 107 mmol/L

628

629

CO2

0 - 27 Days: 15 - 22 mmol/L
28 Days - 11 Months: 20 - 28 mmol/L
>/= 1 Year: 20 - 30 mmol/L

630

631

Anion Gap

10 - 20

632

633

Creatinine

0 - 14 Days: 0.4 - 1.1 mg/dL
15 Days - 11 Months: 0.3 - 0.5 mg/dL
1 - 11 Years: 0.4 - 0.7 mg/dL
12 - 14 Years: 0.6 - 0.8 mg/dL
15 - 17 Years:
Male: 0.7 - 1.1 mg/dL
Female: 0.6 - 0.9 mg/dL
>/= 18 Years:
Male: 0.7 - 1.3 mg/dL
Female: 0.6 - 1.1 mg/dL

634

635

GFR

< 60 mL/min/1.73 sq meter

636

637

Glucose

NICU Inpatient Locations: 51 - 60 mg/dL
0 - 23 Hours: 40 - 60 mg/dL
1 - 11 Months: 54 - 80 mg/dL
>/= 1 Year: 70 - 99 mg/dL

638

639

Hematocrit

Male:
0 - 14 Days: 39.8 - 53.6 %
15 - 30 Days: 30.5 - 45.0 %
31 - 60 Days: 26.8 - 37.5 %
2 - 5 Months: 28.6 - 37.2 %
6 - 23 Months: 30.8 - 37.8 %
2 - 5 Years: 31.0 - 37.7 %
6 - 11 Years: 32.2 - 39.8 %
12 - 17 Years: 33.9 - 43.5 %
>/= 18 Years: 39.4 - 51.6 %

Female:
0 - 14 Days: 39.6 - 57.2 %
15 - 30 Days: 32.0 - 44.5 %
31 - 60 Days: 27.7 - 35.1 %
2 - 5 Months: 29.5 - 37.1 %
6 - 23 Months: 30.9 - 37.9 %
2 - 5 Years: 31.2 - 37.8 %
6 - 11 Years: 32.4 - 39.5 %
12 - 17 Years: 33.4 - 40.4 %
>/= 18 Years: 35.6 - 47.3 %

640

641

Hemoglobin

642

643

Ionized Calcium

1.13 - 1.33 mmol/L

644

645

Potassium

0 - 27 Days: 3.7 - 5.9 mmol/L
28 Days - 1 Year: 4.1 - 5.3 mmol/L
2 - 17 Years: 3.4 - 4.7 mmol/L
>/= 18 Years: 3.5 - 5.1 mmol/L

646

647

Sodium

0 - 26 Days: 133 - 146 mmol/L
27 Days - 1 Year: 139 - 146 mmol/L
2 - 17 Years: 138 - 146 mmol/L
>/= 18 Years: 136 - 145 mmol/L

648

649

TCO2

0 - 27 Days: 15 - 22 mmol/L
28 Days - 1 Year: 20 - 28 mmol/L
>/= 1 Year: 20 - 30 mmol/L

650

651

Troponin (Point of Care):

i-STAT: </= 0.08 ng/mL

652

653

RESPIRATORY (Blood Gas):

654

Prisma Health Baptist Columbia Respiratory Therapy
Taylor at Marion Street
Columbia, SC 29220

Prisma Health Baptist Parkridge Respiratory Therapy
400 Palmetto Health Parkway
Columbia, SC 29212

655

Prisma Health Richland Respiratory Therapy
5 Richland Medical Park Drive
Columbia, SC 29203

Prisma Health Tuomey Hospital Laboratory
129 North Washington Street
Sumter, SC 29150

656

657

PROCEDURE:

REFERENCE:

658

Blood Gas:

659

Arterial:

660

7.35 – 7.45

661

pCO2

35 – 45 mmHg

662

pO2

663

0 - 1 Year:

45 - 100 mmHg

664

1 - 150 Years:

80 - 100 mmHg

665

sO2 (Oxygen Sat)

96.0 – 100.0 %

666

HCO3 (Bicarb)

22.0 – 26.0 mmol/L

667

OxyHemoglobin

95.0 – 98.0 %

668

CarboxyHemoglobin

0.0 – 4.9 %

669

MetHemoglobin

0.0 – 3.00 %

670

671

Venous:

672

7.32 – 7.42

673

pCO2

41 - 51 mmHg

674

pO2

30 - 50 mmHg

675

sO2 (Oxygen Sat)

70.0 – 85.0 %

676

HCO3 (Bicarb)

677

NICU/Newborn Inpatient Locations:

22.0 – 24.0 mmol/L

678

Adult:

22.0 - 26.0 mmol/L

679

OxyHemoglobin

70.0 – 85.0 %

680

CarboxyHemoglobin

0.0 – 4.9 %

681

MetHemoglobin

0.0 – 3.00 %

682

683

Capillary:

684

7.30 – 7.45

685

pCO2

35 - 50 mmHg

686

pO2

45 - 55 mmHg

687

sO2 (Oxygen Sat)

92.0 – 100.0 %

688

HCO3 (Bicarb)

22.0 – 26.0 mmol/L

689

OxyHemoglobin

92.0 – 100.0 %

690

CarboxyHemoglobin

0.0 – 4.9 %

691

MetHemoglobin

0.0 – 3.00 %

692

693

Mixed Venous:

694

7.32 – 7.45

695

pCO2

41 – 51 mmHg

696

pO2

35 - 54 mmHg

697

sO2 (Oxygen Sat)

70.0 – 85.0 %

698

HCO3 (Bicarb)

699

NICU/Newborn Inpatient Locations:

22.0 – 24.0 mmol/L

700

Adult:

22.0 - 26.0 mmol/L

701

OxyHemoglobin

70.0 – 85.0 %

702

CarboxyHemoglobin

0.0 – 4.9 %

703

MetHemoglobin

0.0 – 3.00 %

704

705

Cord Blood - Arterial:

706

7.32 – 7.42

707

pCO2

41 - 51 mmHg

708

pO2

30 - 50 mmHg

709

sO2 (Oxygen Sat)

10.0 – 100.0 %

710

HCO3 (Bicarb)

22.0 – 24.0 mmol/L

711

712

Cord Blood - Venous:

713

7.32 – 7.42

714

pCO2

41 - 51 mmHg

715

pO2

30 - 50 mmHg

716

sO2 (Oxygen Sat)

10.0 – 100.0 %

717

HCO3 (Bicarb)

22.0 – 24.0 mmol/L

718

719

Hematocrit:

720

NICU/Newborn

39.6 – 57.2 %

721

Adult

722

Female:

34.1 – 44.9 %

723

Male:

40.1 – 51.1 %

724

Hemoglobin

725

NICU/Newborn

13.4 – 20.0 g/dL

726

Adult

727

Female:

11.0 – 15.4 g/dL

728

Male:

12.7 – 17.2 g/dL

729

Sodium

730

NICU/Newborn

133 - 146 mmol/L

731

Adult

136 - 145 mmol/L

732

Potassium

733

NICU/Newborn

3.7 – 5.9 mmol/L

734

Adult

3.5 – 5.1 mmol/L

735

Chloride

736

NICU/Newborn

98 - 113 mmol/L

737

Adult

98 - 107 mmol/L

738

Ionized Calcium

1.13 – 1.33 mmol/L

739

Glucose

740

NICU

51 - 60 mg/dL

741

Newborn

40 - 60 mg/dL

742

Adult

70 - 99 mg/dL

743

Lactate

0.5 – 2.2 mmol/L